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7introduction
Lung cancer is the leading cause of cancer related mortality worldwide, ac-
counting for around 27% of all cancer deaths.1 In the Netherlands specifi c-
ally, well over 11.000 new patients are diagnosed with lung cancer every year.2 
Lung cancer is roughly divided by histology into Small Cell Lung Cancer 
(SCLC) and Non-Small Cell Lung Cancer (NSCLC), of which the latter ac-
counts for 85-90% of all cases.3 During the last decade, the medical profes-
sional has witnessed that lung cancer, especially NSCLC, has become much 
more complex and treatment has gained a more individualized character. 
The diagnosis of lung cancer nowadays requires more than just pathological 
confirmation of the diagnosis. Accurate staging is necessary to ascertain the 
extent of the disease as this stratifies patients into lower and higher risk 
groups, which is important for prognostication, patient management and 
optimal treatment decisions. Furthermore, in recent years lung cancer ther-
apy for the higher incurable stages has become driven by tumor type4 and for 
the large group of NSCLC adenocarcinoma subtype patients by gene muta-
tion status.5 Both developments have led to the necessity of performing mul-
tiple diagnostic procedures, of which 18F-fluorodeoxy-glucose-Positron Emis-
sion Tomography and contrast enhanced Computed Tomography (FDG-PET/
CT) precluded probably the most important change in diagnostic care for 
lung cancer. Compared to conventional Computed Tomography (CT), FDG-
PET/CT proved to be superior in defining lung cancer stage mostly by reveal-
ing occult metastasis but also in more accurately predicting lymph node 
metastases.6-8 Management decisions for individual lung cancer patients 
were influenced to such an extent that FDG-PET/CT rapidly became a pri-
mary diagnostic tool in lung cancer, and implementation in all major guide-
lines followed. 
Pathological confirmation of diagnosis and disease stage may require – even 
within the same patient – several procedures including (but not exclusively) 
bronchoscopy, percutaneous needle biopsy, esophageal endoscopic ultra-
sound (EUS), endobronchial ultrasound (EBUS) or mediastinoscopy; often 
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8multiple of these techniques are used in the same patient. In combination 
with the high lung cancer incidence rates described above this can be chal-
lenging for medical practice and requires, besides resources, organization 
and timing of health care. Timeliness of care has gained attention in recent 
years: Not only may delays adversely affect disease stage9,10 and survival,10-13 it 
can also be seen as a care quality indicator. And still, although maximum 
acceptable waiting times for referral, diagnosis and start of therapy in lung 
cancer have been explicitly formulated in both national and international 
guidelines,14-17 these intervals are often reported to be longer than recom-
mended.18 It has been shown that diagnostic algorithms in the sense of a 
Rapid Outpatient Diagnostic Pathway (RODP) – in the past also referred to as 
‘one stop’ or ‘two stop’ pathway – most successfully improved timeliness,18 
but these improvements were demonstrated in an era that preceded intro-
duction of most of all previously mentioned diagnostic and staging tools that 
presently have such importance and comprise much more than just ‘two 
steps’.
Despite all abovementioned developments that have broadened the diagnos-
tic and therapeutic horizon for certain subgroups of patients, lung cancer 
has at diagnosis often already advanced to an extent that excludes curative 
treatment, resulting in a very modest overall 5 year survival rate that has 
shown only a small improvement over the last decades and is presently esti-
mated at 18%.1 From a patient’s perspective, the confrontation with a pos-
sible diagnosis of lung cancer may be very distressing21 not only because of 
this poor prognostic nature of the disease, but possibly also in face of the 
sometimes invasive diagnostic procedures that may be required to ascertain 
diagnosis and stage. Notably, lung cancer patients experience distress levels 
that are among the highest of all cancer types ranging from 20 to even 50% 
anywhere during the course of their disease;19,20 as such they may be seen as 
a patient group that is more at risk.
Distress is usually characterized by anxiety or depressive symptoms and is 
best described by the National Comprehensive Cancer Network (NCCN) def-
inition as ‘a multifactorial unpleasant emotional experience of psychologi-
cal (cognitive, behavioral, emotional), social and/or spiritual nature that may 
interfere with the ability to cope effectively with cancer, its physical symp-
toms and its treatment’. 22 And although medical practice strives to provide 
answers to the physical and mental needs of lung cancer patients in terms of 
curative and palliative care, the needs of suspected patients facing the pos-
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9sibility of this diagnosis receive much less attention despite the fact that 
these patients experience multiple more or less invasive diagnostic proce-
dures during a period of uncertainty. Moreover, a considerable number of 
patients are eventually not diagnosed with cancer but undergo the same pro-
cedures and experience similar distress. Furthermore, if the recent calls for 
implementation of lung cancer screening23 are adopted, numbers of suspect-
ed lung cancer patients that undergo diagnostic analysis for an eventual 
benign result will increase substantially. It is important to realize that for 
many patients this ‘benign outcome’ does not automatically result in a ‘be-
nign experience’, as has been exemplified by breast cancer screening studies 
showing that psychological consequences of screening may persist in pa-
tients with benign results.24
In order to address both timeliness and the substantial number of new sus-
pected patients that is referred on a daily basis, medical practice needs to 
review diagnostic care thoroughly and implementation of an RODP may be 
the most logic step further. Moreover, a timely diagnosis could actually re-
duce distress levels by drastically shortening the period of uncertainty. Na-
tional discussion on this subject among medical professionals25-27 but also 
patient advocate non-governmental institutions28 is still alive today. Howev-
er, the debate on the specific advantage or disadvantage of an RODP in pa-
tient distress remains unsettled since it is based on assumptions and per-
sonal experience, but not empirics.
The studies presented in this thesis address the diagnostic pathway in sus-
pected lung cancer patients and focus on the possible improvements in di-
agnostic timeliness, patient reported distress and quality of life (QoL), when 
a standardized fast track approach by means of an RODP is used. Further-
more, these studies investigate the diagnostic performance of FDG-PET/CT 
when incorporated as a first-line diagnostic tool within the RODP. 
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outline of this thesis
This thesis provides a comprehensive analysis of the characteristics of the 
RODP of the Radboud university medical center (Radboudumc) and focuses 
on the diagnostic performance of FDG-PET/CT, which is included in this 
RODP as a routine diagnostic tool. Furthermore, distress and QoL during the 
diagnostic episode of a possible malignancy will be described in an overview 
of published literature and the beneficial effects of an RODP in reducing 
distress will be discussed.
Chapter 2 describes the diagnostic results of the RODP for suspected lung 
cancer patients, including routine FDG-PET/CT and the characteristics of all 
analyzed patients during the first ten years after its implementation at Rad-
boudumc in 1999. It explores the accuracy of the diagnosis in this rapid set-
ting and puts timeliness of diagnostic care for suspected lung cancer pa-
tients in the perspective of delays described in literature12 and the limitations 
as published in guidelines.8-11 Furthermore, it describes the impact of symp-
tomatology and referral type on different types of delay (patient, referral, 
diagnostic and therapeutic delay) and it addresses the complex question 
whether these delays can be related to disease stage and patient outcome. 
Chapter 3 focuses specifically on the subset of patients in this RODP whose 
referral was based on an abnormal chest X-ray. This is an important sub-
group of the cohort described in the previous chapter, as in the clinical prac-
tice of primary care most lung cancer suspicions start with the abnormal 
chest X-ray that the general practitioner has ordered. Therefore, the diagnos-
tic performance of the FDG-PET/CT in separating malignancy from benign 
lesions within the programmed setting of an RODP is vital, as the FDG-PET/
CT is not performed after diagnostic CT in the regular sequential setting. 
The next two chapters attempt to answer the question whether an RODP will 
influence distress and QoL. In the past, some research has been performed 
on this subject but these results do not automatically lead to straightforward 
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answers as different measures have been used in different circumstances to 
different patient subgroups. Chapter 4 systematically reviews the literature 
regarding distress and QoL during the diagnostic evaluation of a suspected 
malignancy in order to attempt to shed light on whether a rapid diagnosis 
should be preferred in this respect, with the subgroup of suspected lung 
cancer patients in mind which might be generally more at risk.19,20 RODPs 
have been developed for different cancer types but the effect of this different 
approach on suspected lung cancer patients’ distress levels and QoL had not 
yet been prospectively evaluated. We therefore decided to perform a study in 
suspected patients who underwent an RODP and patients who underwent a 
regular Standard Diagnostic Approach (SDA). This PENELOPE study (Pulmo-
nary Evaluation of NEoplastic Lesions in Outpatients and it’s Psychological 
Effects) was performed in a prospective cohort design in four different med-
ical centers in the Netherlands, which enabled inclusion of a large number 
of patients that were analyzed in an RODP or SDA. Results are described in 
Chapter 5. The thesis concludes with a summary and discussion of the 
main results of our research in Chapter 6.
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ABstrAct
IntroduCtIon: Delays in the diagnosis of lung cancer are under debate and 
may affect outcome. The objectives of this study were to compare various 
delays in a rapid outpatient diagnostic program (RODP) for suspected lung 
cancer patients with those described in literature and with guideline recom-
mendations, to investigate the effects of referral route and symptoms on 
delays, and to establish whether delays were related to disease stage and 
outcome. 
Methods: A retrospective chart study was conducted of all patients with 
suspected lung cancer, referred to the RODP of our tertiary care university 
clinic between 1999 and 2009. Patient characteristics, tumor stage and dif-
ferent delays were analyzed.
results: Medical charts of 565 patients were retrieved. 290 patients (51.3%) 
were diagnosed with lung cancer, 48 (8.5%) with another type of malignancy, 
and in 111 patients (19.6%) the radiological anomaly was diagnosed as non-
malignant. In 112 (19.8%) no immediate definite diagnosis was obtained, 
however in 82 of these cases (73.2%) the proposed follow-up strategy con-
firmed a benign outcome. The median first line delay was 54 days, Interquar-
tile Range (IQR) 20–104 days, median patient delay 19 days (IQR 4-52), median 
referral delay was 7 days (IQR 5-9 days), median diagnostic delay 2 days (IQR 
1-19 days). In 87% a diagnosis was obtained within 3 weeks after visiting a 
chest physician and 52.5% started curative therapy within 2 weeks after di-
agnosis. Patients presenting with hemoptysis had shorter first line delays. 
The RODP care was generally far more timely compared to literature and 
published guidelines, except for both referral and palliative therapeutic de-
lay. No specific delay was significantly related to disease stage or survival.
ConClusIons: An RODP results in a timely diagnosis well within guideline 
recommendations. Patient and first line delay account for most of total pa-
tient delay. Within the limitations of this retrospective study, we found no 
association with disease stage or survival.
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introduction
Lung cancer is the leading cause of cancer related mortality in men and sec-
ond in women. The 5 year survival rate of the various types of lung cancer for 
both Europe and the United States is approximately 16% and did not sig-
nificantly improve in the last decade, despite emergence of new diagnostic 
and therapeutic developments.1 The necessity to perform diagnostic proce-
dures such as 18fluorodeoxyglucose Positron Emission and contrast enhanced 
Computerized Tomography scan (FDG-PET/CT), mediastinoscopy or Esoph-
ageal endoscopic Ultrasound (EUS) and Endobronchial Ultrasound (EBUS), 
in combination with the high lung cancer incidence rates can be challenging 
and, besides resources, requires organized and timely health care. Timeli-
ness has gained attention in the recent years since delays may affect disease 
stage2,3 and survival.2-6 
Although consensus based, maximum acceptable waiting times for referral, 
diagnosis and start of therapy in lung cancer have been explicitly formulated 
in several guidelines.7-10 These can be as general as 2 months for referral, 
diagnosis and start of therapy together,8 or rather specific: Referral delay is 
then limited to 1 week7 or 80% of patients seen within 5 days;9,10 diagnostic 
delay to 2 weeks,7 or 80% of patients diagnosed in either 3 weeks or 5 when 
mediastinoscopy is needed;9,10 therapeutic delay can take 1 to 6 weeks de-
pending on urgency and therapy type.7-10 A recent comprehensive review of 
the literature on timeliness of lung cancer care shows however that time in-
tervals to diagnosis and treatment are often longer than guidelines recom-
mend.11 It furthermore demonstrates that most published literature address-
es timeliness of treatment or referral and that diagnostic delay is discussed 
to a much lesser extent although it can be a deeply disturbing experience for 
suspected cancer patients accompanied by high distress levels.12 The fact 
that distress in the diagnostic phase has been shown to be reduced by short-
ening this period13-17 indicates this should be addressed by effective interven-
tions such as implementation of urgent referral guidelines,18 multidisci-
plinary meetings,19-21 nurse-led care,22 or specific diagnostic algorithms.23 
These algorithms and more complicated two-stop pathways most success-
fully improve timeliness11 although the evidence so far is limited to a few 
studies24,25 and did not include FDG-PET/CT, nowadays being considered the 
best imaging technique in lung cancer.26,27 
With the present study, we hope to add to the knowledge on rapid pathways. 
We retrospectively reviewed all patients referred between 1999 and 2009 to 
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PET/CT and contrast enhanced chest CT
Multidisciplinary evaluation of PET/CT
Pulmonary function testing
Physician visit, physical examination, discussion of PET/CT
DaY 2 (Thursday)
Bronchoscopy
Discussion of cytology results
the two-day Rapid Outpatient Diagnostic Program (RODP) including the 
unique feature of FDG-PET/CT for all patients with suspected lung cancer 
that was implemented in the Radboud University Nijmegen Medical Centre 
(RUNMC) in 1999. Our aims were to describe the diagnostic results of the 
RODP, to evaluate the impact of symptomatology and referral type on diffe-
rent types of delay, to establish whether delays were related to outcome and 
stage, and to compare the delays with those described in literature and 
guideline recommendations. To our knowledge this is the first study report-
ing on timeliness of an RODP incorporating integrated FDG-PET/CT. 
Methods
A retrospective chart review was conducted of all consecutive patients re-
ferred to the RODP between August 1999 and April 2009. In this period, all 
outpatients with a radiological suspicion of lung cancer without clinical 
need for hospitalization or obvious stage iv disease were diagnosed in this 
program in our centre. All patients underwent a full diagnostic workup 
(FDG-PET/CT, consultation of a chest physician, pulmonary function tests, 
bronchoscopy) and disclosure of the cytology results (based on Papanicolau 
and Giemsa staining), in two days time as explained in Table 1. 
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FIGURe 1    schematic representation of delays 
first symptom
patient delay
first Line delay second line delay
GP delay referral delay diagnostic delay therapeutic delay
first GP visit referral first specialist visit diagnosis start treatment
Demographic data, clinical characteristics and dates required to calculate 
delays and survival were retrieved from medical charts. Since the RUNMC is 
a large university hospital and a tertiary referral center for oncology, many 
patients were referred by other specialist consultants. In order to assess and 
compare both tertiary and primary care, demographic characteristics, diag-
nostic results and outcome were recorded by referral (general practitioner 
(GP) or specialist). Finally we defined the patient subgroup with a histologi-
cally or cytologically confirmed lung cancer diagnosis. Patient characteris-
tics and delays were compared within groups. All patients were staged ac-
cording the international staging system version 6.28
Different delays were defined as shown in Figure 1: Patient delay as the time 
from first symptom until the first visit to a GP, GP delay as the time between 
first GP visit and referral to a chest physician, referral delay as the time be-
tween referral (written or by phone) and first RODP day, diagnostic delay as 
the time between first RODP day and date of final (accurate) diagnosis, ther-
apeutic delay as the time between diagnosis and start of treatment. In agree-
ment with several studies11 and both British Thoracic Society (BTS)7 and 
Dutch10 guidelines defining diagnostic delay as the interval between first 
visit and start of treatment, we also calculated this interval (‘diagnostic + 
therapeutic delay’) to facilitate comparison. All waiting time intervals were 
calculated in calendar days (including weekend and holidays) only if both 
dates defining that delay had been recorded. 
All data were analyzed using the SPSS 16.0 statistical software program 
(SPSS, Chicago, IL). Descriptive statistics were used to summarize the demo-
graphic data. We report the mean and standard deviation (SD) in case of 
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normally distributed continuous variables, and median and interquartile 
range (IQR) for variables that are not normally distributed. Continuous vari-
ables were compared using the unpaired t-test or Mann-Whitney-U test, cat-
egorical variables were compared using the χ2-test, delay per stage was com-
pared using the Kruskal-Wallis test. The Cox proportional hazard model was 
used to analyze survival per delay. Differences were considered statistically 
significant if p< 0.05. 
results
DemograPhiC Data
Of the total of 570 RODP patients, of 565 medical charts could be retrieved. 
Table 2 shows demographic patient data. Two hundred and eight patients 
had been referred by their GP, 355 by a specialist. The remaining 2 patients 
were self-referrals to the emergency ward, included in the RODP afterwards. 
Two patients (indicated by ECOG performance status 5 in table 2) died either 
before start of, or during the RODP but were included in calculations of prior 
delays. For all 565 patients mean age was 63.9 years, 66.5% were male and 
10.8% were never smokers. Prevalence of COPD was 59%, with 6.7% Global 
initiative for Chronic Obstructive Lung Disease (GOLD) stage iii or iv. A his-
tory of some form of cancer was noted in 324 patients (41.4%), significantly 
more often in specialist referred compared to GP referred patients (51.0 ver-
sus 25.5%) as was non-pulmonary co-morbidity (62.5% versus 49.0%, both 
p<0.05). Table 3 shows that 290 patients (51.3%) were diagnosed with lung 
cancer, of which 261 patients (90%) had Non-Small Cell Lung Cancer (NSCLC), 
16 (9.0%) Small Cell Lung Cancer (SCLC) and 3 (1.0%) a double tumor consist-
ing of both cell types. In 211 of all 290 lung cancer cases (72.8%) additional 
staging procedures to define clinical and/or pathological tumor stage were 
required. One hundred and fifteen patients (20.4%) had a certain benign 
diagnosis (most often infection) and from 112 patients (19.8%), no cytologi-
cally or histologically confirmed diagnosis was obtained. In 82 of these in-
definite cases (73.2%) the proposed follow-up strategy (median follow-up 32 
months, range 9 weeks to 10 years) confirmed a benign outcome. The re-
maining 28 (26.8%) were estimated to have a probable lung cancer but fur-
ther analysis was abandoned because of poor performance status or patient 
refusal of further diagnostic procedures. 
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table 2    patient characteristics
Numbers (%) or means (SD); ECOG: Eastern Cooperative Oncology Group; COPD: Chronic  
Obstructive  Pulmonary Disease; GOLD: Global initiative on Obstructive Lung Disease; GP:  
General Practitioner; * non-pulmonary co-morbidity requiring treatment or follow-up by  
specialist physician in the last 5 years. 
   Patients 
N   565
Mean age   65.9 (10.0)
Sex: Male  376 (66.5)
 Female  189 (33.5)
ECOG Performance status at presentation 
 0  387 (68.5)
 1  138 (24.4)
 2  32 (5.7)
 3  6 (1.1)
 4  2 (0.4)
Weight loss > 10%  60 (10.6)
Significant co-morbidity*  324 (57.3)
COPD:   332 (58.8)
 GOLD I + II  291(51.5)
 GOLD III + IV  41 (7.3)
Cigarette smoking: 
 current  152 (45.4)
 ex-smoker  162 (48.8)
 never-smoker  16 (4.8)
Mean pack year history (min-max) 32.8 (1-125)
Any history of cancer  234 (41.4)
History of more than one cancer 34 (6.0)
History of cancer >1  and < 5 years 62 (11.6)
History of cancer < 1 year  74 (13.1)
Symptoms  
 Any   387 (68.5)
 None or nonspecific    218 (38.6)
RODP inclusion based on: 
 Chest X-ray  413 (73.5)
 CT-scan  144 (52.5)
 PET-scan  6 (1.1)
P.Brocken_170x240mm_bw_v13.indd   20 05-01-15   14:32
21
table 3    rodp diagnostic results (all patients), numbers of patients (%) 
NSCLC: Non Small Cell Lung Cancer; SCLC: Small Cell Lung Cancer; BSC: best supportive care. 
*Of the 3 SCLC/NSCLC synchronous tumours, cytology diagnosis was correct in 1, yielded 
squamous cell carcinoma in another, and non-malignant in the last.
   total grouP lung cancer grouP 
N   565 290
Diagnosis: 
NSCLC   261 (46.2) 261 (90.0)
SCLC   26 (4.6) 26 (9.0)
Synchronous  NSCLC & SCLC 3 (0.5) 3 (1.0)
Benign   115 (20.3)
Metastasis  43 (7.6)
Mesothelioma  4 (0.7)
Thymoma  1 (0.2)
No tissue diagnosis  112 (19.8)
 most likely benign 82 (14.5) 
 most likely cancer  28 (5.0)
 patient died before diagnosis 2 (0.4)
Underwent bronchoscopy  533 (94.3) 279 (96.2)
Diagnosis by RODP, no other procedures  240 (42.5) 165 (56.8)
Pathology diagnosis by other procedure 207 (36.6) 125 (43.3)
RODP-cytology (% of final diagnosis)*:
NSCLC  (NSCLC)  127 (43.8)
Non-malignant (NSCLC)  124 (42.8)
SCLC  (SCLC)  13 (4.5)
Non-malignant (SCLC)  11 (3.8)
NSCLC  (SCLC)  2 (0.7)
SCLC  (NSCLC)  2 (0.7)
Lung cancer therapy: Curative  151 (52.1)
  Palliative  85 (29.3)
  BSC  54 (18.6)
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timeliness – analYsis of DelaYs
Thirteen patients with exceptionally long diagnostic delays were excluded for 
delay analysis for the following reasons: solitary pulmonary nodules as-
signed to routine follow-up showing growth after more than 1 year (after 
re-evaluation malignancy (n=7, mean interval 385 days) and atypical myco-
bacteriosis (n=1, 126 days)), the necessity to perform surgery for other can-
cers prior to starting the further diagnostic work-up for the pulmonary le-
sion (n=3, mean 58 days), or postponement of procedures by the patient (n=2, 
mean 65 days). 
Results of the delay analysis for the remaining 552 patients are summarized 
in Table 4. Within first line delay, median patient delay was 19 days for all, 
and 22 days for lung cancer patients. GP delay stretched 15 days and 18 days 
respectively. Median referral delay of the RODP was 7 calendar days (5 work-
ing days), 80% of all patients were seen by a chest physician within 12 calen-
dar days (or 8 working days since the RODP was fixed to Wednesdays and 
Thursdays). Patient and referral delay were not statistically different between 
GP and specialist referred groups. Median diagnostic delay was 2 days, 80% 
of patients were diagnosed within 20.8 days. Lung cancer patients reviewed 
separately had equal diagnostic delay with 80% diagnosed within 20.0 days; 
if these patients required surgical staging by means of mediastinoscopy, 
80% was diagnosed and staged within 29 days. Median diagnostic delay was 
significantly longer for specialist referred patients (6 days (IQR 1-20)) com-
pared to GP referred patients (1 day (IQR 1-6)), and also when CT guided 
needle biopsies or mediastinoscopy were required, but not in case of EUS, 
cerebral CT or MRI.
Median therapeutic delay for curatively intended (stage i-iiia) and palliative 
(stage iiiB-iv) therapy was 18 (IQR 0-25) days and 21.5 (IQR 12-33.5) days, re-
spectively. Eighty percent started palliative therapy within 40.0 days and cu-
ratively intended therapy within 27.2 days, 31.4 days if a mediastinoscopy 
was required. The 26 patients diagnosed with small-cell lung cancer (SCLC) 
had a significantly shorter median therapeutic delay of 7.5 days (IQR 4.75-
12.25), as compared to 20 days (IQR 6-28) for NSCLC (p=0.003). In our study 
the interval of ‘diagnostic + therapeutic delay’ spanned a median 26 (IQR 
18-40, n 252) days; 80% of patients started therapy within 39 days. The 143 
patients with curatively intended therapy for which we could calculate this 
interval had similar results (25 (IQR 19-35) days, 80% within 39 days, 41 days 
if mediastinoscopy was needed).
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 all Patients (n=552)              lung cancer Patients (n=280) 
 N Median (IQR) N Median (IQR)
Patient delay 107 19.0 (4-52) 63 22.0 (7-78)
GP delay 120 15.0 (6-35.5) 69 18.0 (6-46)
First Line delay 211 54.0 (20-104) 130 60.0 (24.75-119.5)
Referral delay 473 7.0 (5-9) 236 7.0 (5-9)
Diagnostic delay 450 2.0 (1-19) 280 2.0 (1-17.5)
Diagnostic + Therapeutic delay*  215 25.0 (18.0-39.0)
Therapeutic delay Any  215  19.0 (6.5-27)
 Curative therapy 143 18.0 (0-25)
 Palliative therapy 72 21.5 (12-33.5)
Second Line delay   219 36.0 (26-46)
table 4    Timeliness: delays in days 
N = patients with known dates, see figure 1. *this interval has been used by some other studies to define 
‘diagnostic delay’.  
timeliness - lung CanCer stage anD outCome
Clinical and pathological lung cancer stage for all NSCLC patients and their 
survival are presented in Table 5. Between GP and specialist referred groups, 
the only statistically significant difference was seen in the incidence of clin-
ical stage ia (4.3% versus 13.8%, p < 0.05) and pathological stage ib (10.1% 
versus 33.3%). When all defined delays were analyzed per stage, diagnostic 
delay was inversely related to clinical stage (Kruskal-Wallis, p=0.008), while 
therapeutic delay showed the opposite being longer for higher stage patients 
(p=0.001). However, when patients with a diagnostic thoracotomy (with long-
er diagnostic and short therapeutic delay) were excluded, none of the delays 
showed a relation with clinical stage and no specific delay was related with 
pathological stage. Limiting the analysis to GP referred patients did not 
change the outcome. 
Median overall survival for all NSCLC patients was 17 months (95% CI 29.5-
41.3). When survival time was analyzed per delay, the Cox proportional haz-
ards model showed no relation between any delay and survival. 
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stage clinical  Median Pathological Median 
 (n=261)  survival (n=100) survival 
Ia 40 (15.3) 45 35 *
Ib 43 (16.5) 35 26 110
IIa 3 (1.1) 32 2 6
IIb 6 (2.3) 17 17 35
IIIa 48 (18.4) 12 10 19
IIIb 43 (16.5) 16 7 10
IV 78 (29.9) 6 3 28
Overall  17  53
table 5    survival per clinical and pathological lung cancer stage 
Patient numbers (%) and median survival per stage (months) for the 261 NSCLC patients,  
* median survival was not reached.  
sYmPtoms, DiagnostiC PerformanCe of roDP bronCho sCoPY 
anD DifferenCes bY referral
The most frequent single presenting symptom was cough (22.4%), followed 
by hemoptysis (8.5%), pain (5.8%), dyspnea (5.3%) and fatigue (4.1%). Consid-
erably more patients (55.8%) in the specialist-referred group were asympto-
matic or had non-specific symptoms like fatigue or weight loss compared to 
the GP referred group (9.6%, p<0.05). As presenting symptom, only hemop-
tysis was associated with shorter median patient, GP or referral delay (4, 6 
and 6 days, respectively, p< 0.05).
Thirty two of the 565 patients did not undergo the RODP bronchoscopy for 
various reasons (most often exclusion of malignancy after reviewing the 
FGD-PET/CT, 28 cases). In the remaining 533 patients, RODP bronchoscopy 
tissue samples rendered a cytological or histological diagnosis in 240 (42.5%) 
patients and in 165 of the 279 lung cancer patients that underwent bronchos-
copy (59.1%). Despite the fact that 170 lung cancer patients (60.9%) had no 
visible endobronchial abnormalities, cytological examination did yield ma-
lignant cells in 67 of these cases (39.4%). In 135 (48.4%) of the 279 lung cancer 
patients, the initial cytology samples rendered a benign diagnosis due to 
sampling error. For the remaining 144 lung cancer patients, RODP cytologi-
cal diagnosis was accurate when compared to the bronchoscopy histology 
results that were reported in the same week in 140 cases (97.2%). 
Specialist compared to GP referred patients were less frequently diagnosed 
with primary lung cancer but more often with pulmonary metastasis (45.4% 
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versus 60.6 % and 9.6% versus 4.3%, respectively, both p< 0.05). GP-referred 
patients received an accurate diagnosis based on the RODP findings alone in 
58.2% of cases compared to 33.5% in the specialist referred patient group, 
which required significantly more often additional diagnostic procedures to 
confirm the diagnosis (p< 0.05). 
discussion
Although FDG-PET/CT is considered the best imaging technique in lung can-
cer staging26,27 and feasibility of FDG-PET/CT in an RODP setting has already 
been shown29 it has not been used as standard care in RODP studies pub-
lished so far. This is the first study to demonstrate that an RODP for sus-
pected lung cancer patients including routine FDG-PET/CT is a feasible and 
accurate logistical outpatient program capable of reducing median diagnos-
tic delay to only 2 days. 
These findings are relevant since this may reduce the time of exposure to 
high distress levels awaiting a possible diagnosis of a cancer12 with high in-
cidence rates.1 Moreover, the results show that timely care was achieved by a 
relatively simple program that can be instituted in any medical centre with 
access to an FGD-PET/CT. Other studies have demonstrated improvement of 
timeliness by a two-stop rapid pathway24,25 or a centrally coordinated algo-
rithm23 yet not to this extent.
timeliness
Timeliness of lung cancer care starts with timely recognition of symptoms 
by patients themselves, which is often inadequate or delayed.30,31 This is il-
lustrated by the fact that the median first line delay in our study lasted al-
most 2 months although the 19 day median patient delay was in the lower 
range of other values reported (median 14-42 days).4,32-36 The patient samples 
for which patient and GP delay could be calculated were different and much 
smaller than for first line delay (n=107, 120, and 211, respectively, table 4) so 
whether patient or GP delay is the bigger factor within first line delay remains 
unclear. Furthermore, we could not correct for factors influencing whether 
and when patients actually seek help.37
Referral delay in our study was 7 days and, despite the fixed weekly schedule, 
shorter than most reported referral delays (ranging 7-12 days).11 Only the UK 
study by Devbhandari et al. reported a shorter 1 day (IQR 0-5) median referral 
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delay.38 The RODP however demonstrated the strongest effect on diagnostic 
and second line delay; the median diagnostic delay of 2 days for both the 
total group and lung cancer patients specifically is substantially shorter than 
reported delays of 7-37 days in other studies.3,4,19,23-35,38,39 Obviously, for most 
patients the diagnostic episode was not completed yet and many patients 
required additional interventions to define disease stage. Nevertheless, the 
RODP succeeded to maintain timeliness compared to other studies since the 
median ‘diagnostic + therapeutic delay’ interval spanned 26 days (table 4) 
and 80% of patients started therapy within 39 days. Similarly defined re-
ported median delays range 31-104 days.20,32,40,41 An RODP by definition does 
not specifically reduce therapeutic delay. However, the median therapeutic 
delay of 19 days is in the low range of other studies reported (12.5-52 days).1,42,43 
On the other hand, lung cancer patients requiring surgical therapy had a 
longer median therapeutic delay of 34 days (IQR 27-43, n=87 patients). 
Only 2 other studies specifically report on RODPs and delay in lung cancer; 
both were performed in an era when FDG-PET/CT was not yet available. La-
roche et al.24 reported on a two stop investigation service reducing the me-
dian consultation to surgery interval by 50% to 5 weeks; however only 9% of 
patients had to undergo further staging procedures. The numerically small-
er study by Murray et al.25 comprised all therapy types and showed this inter-
val reduced to even 3 weeks, but did not report on further staging. Delay 
types other than consultation to therapy were not investigated in both stud-
ies. 
DelaYs anD outCome
We found no clinically relevant differences in any delay in patients diag-
nosed with either locoregional (stage ia-iiia) or advanced disease (stage iiib-
iv), except for shorter diagnostic delay in lower clinical stage patients and 
longer therapeutic delay in higher clinical stage patients. This difference 
may be explained by the 19 patients that underwent diagnostic thoracotomy 
for a suspicious nodule. Fifteen of these were diagnosed with NSCLC in a low 
disease stage (mostly ia) with by our definition a long diagnostic delay (me-
dian 29.0 days) and short therapeutic delay (0 days). After exclusion of this 
category no differences in disease stage or survival could be attributed to any 
delay. The influence of delays on stage and survival is under debate as both 
positive5,6,44 and negative effects4,40,45,46 have been reported; our findings are in 
line with studies showing absence of any effect.2,33,47-49 The fact that in our 
study, compared to the studies mentioned, more patients were referred by 
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specialists was not a factor: limitation of the analysis to GP referred patients 
(who more frequently had symptoms) did not change outcome. 
ComParison with guiDeline reCommenDations
Our median referral delay of 7 days complies with BTS, RAND corporation 
and American College of Chest Physicians (ACCP) guideline limits,7-9 but is 4 
days longer than recommended in the Dutch guideline.10 This may be ex-
plained by the restriction of the RODP to fixed days in our center (Wednesday 
and Thursday) limiting instant access. However, longer referral delay was 
compensated by shorter diagnostic delay. The RODP was not specifically de-
signed to reduce therapeutic delay, but adhered to BTS and RAND guide-
lines. The Dutch guideline defines therapeutic delay as the time elapsing 
between the decision to treat and actual start of treatment rather than the 
time between diagnosis and treatment in our study. Its aim is to start treat-
ment for at least 80% of patients within 2 weeks, after a maximum diagnos-
tic interval of 3 weeks (or 5 weeks if mediastinoscopy is required). For a more 
accurate comparison with this guideline, we calculated the interval between 
the second RODP day and start of therapy. Of the curatively treated patients 
80% started therapy within 34 days, 41 days if mediastinoscopy was needed. 
However 80% of palliative treatment started within 42 days, which exceeds 
the guideline limit for palliative treatment (80% within 24 days). Whether 
this difference is justified can be debated, as large numbers of patients do 
not require immediate palliative therapy and the detrimental effect of a 2 
week delay on start of palliative therapy on survival has never been estab-
lished. 
DiagnostiC PerformanCe
The long diagnostic delay we found for a number of patients confirms that 
for a subgroup of patients it may be difficult to obtain a tissue diagnosis. This 
was illustrated by the fact that CT guided needle biopsy and mediastinos-
copy significantly increased diagnostic delays in our study. Especially spe-
cialist referred patients needed more diagnostic procedures, probably due to 
the fact that these patients presented with smaller lesions which frequently 
require multiple diagnostic procedures. Local availability of diagnostic and 
staging techniques will influence timeliness particularly for this more diffi-
cult to diagnose subgroup, yielding opportunities for improvement. 
In the RODP, bronchoscopy was used for nearly all patients, irrespective of 
type, localization or visibility of the intrapulmonary lesions. This might ex-
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plain both the relatively high number of non-diagnostic pathology results 
and the mismatch of around half of the initial cytological diagnosis com-
pared to the final lung cancer diagnosis. However, retrospectively this led to 
treatment strategy change in only 4 cases in which NSCLC had been mis-
taken for SCLC and vice versa; malignant cytology results were therefore very 
accurate. Bronchoscopic cytology yield may be improved by ultrasound guid-
ed biopsies or EBUS50,51 but these techniques were not routinely used in the 
RODP between 1999 and 2009.
limitations
This study has some limitations. Data were obtained from patient records 
and GP referral letters making them susceptible to recall bias and underre-
porting, and some of the retrospective data are incomplete, limiting the 
quality of conclusions on delays. Furthermore, this is a single (tertiary care) 
centre study which can lead to a certain referral bias. The fact that the Dutch 
oncology health care system, in contrast to e.g. the United States42 has public 
hospitals only, rules out health care system bias. Finally, one fifth of all pa-
tients were finally diagnosed with benign disease: Although common in 
clinical practice, it is a confounding factor when comparing results with 
other studies. On the other hand, suspected patients eventually not diag-
nosed with cancer have similar emotional distress of the diagnostic epi-
sode16,17,52 and may therefore equally benefit from a rapid diagnosis.
conclusion
Despite not being influenced by an RODP, awareness among patients needs 
to be improved since patient delay is the largest of all defined delays. How-
ever, an RODP including FDG/PET-CT is a valid instrument to achieve, for the 
majority of suspected lung cancer patients, care that is both more timely 
than the shortest guideline limits, and more timely compared to what has 
been published so far.
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ABstrAct
BaCkground: The diagnostic evaluation of patients presenting with pos-
sible lung cancer is often complex and time consuming. A Rapid Outpatient 
Diagnostic Program (RODP) including 18F-fluorodeoxy-glucose-Positron 
Emission Tomography (FDG-PET) and contrast enhanced Computed To-
mography (CT) as a routine diagnostic tool may improve timeliness, however 
the diagnostic performance of such RODP combined approach remains un-
clear.
oBjeCtIves: We evaluated timeliness of care and diagnostic performance of 
FDG-PET and contrast enhanced CT (FDG-PET/CT) in an RODP for all pa-
tients referred with a chest X-ray suspicious of lung cancer. 
Methods: Charts of patients referred to the two-day RODP of our tertiary 
care university clinic after an abnormal chest X-ray between 1999 and 2009 
were reviewed. Between 1999 and 2005 co-registered FDG-PET and CT imag-
ing took place; from September 2005 onwards a hybrid system was used. We 
analyzed timeliness of care and diagnostic performance of FDG-PET/CT to 
differentiate malignant from benign lesions.
results: In 386 patients available for analysis, 260 were diagnosed lung can-
cer, 23 had another type of malignancy, 78 had certain benign disease, and 
in 45 the diagnosis was not pathologically confirmed but a median 24.5 
months follow up confirmed a benign outcome. Sensitivity, specificity, nega-
tive predictive value, positive predictive value and accuracy of FDG-PET/CT 
to differentiate lung cancer from benign disease were 97.7%, 60.2%, 92.5%, 
84.0% and 85.8% respectively. Lung cancer patients had a median referral, 
diagnostic and therapeutic delay of 7, 2 and 19 days, respectively. 
ConClusIons: FDG-PET/CT in an RODP setting for suspected lung cancer 
has high performance in detecting cancer and facilitates timely care.
introduction
Lung cancer is the leading cause of cancer-related death in both men and 
women. The 5-year survival rate in the western world of the various types of 
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lung cancer combined is approximately 16% and has not significantly im-
proved in the last decade,1 despite constant new diagnostic and therapeutic 
developments. Obtaining a correct lung cancer diagnosis and stage is com-
plex and may require multiple modalities such as 18F-fluorodeoxy-glucose-
Positron Emission Tomography (FDG-PET), Computed Tomography (CT), 
bronchoscopy, Endoscopic Ultrasound (EUS), CT-guided biopsy and some-
times many more. In clinical practice this has a tendency to negatively influ-
ence timeliness of lung cancer care. Many interventions have been reported 
to improve diagnostic delay, such as implementation of urgent referral 
guidelines, 2 multidisciplinary meetings,3-5 nurse-led care6 or two-stop path-
ways.7,8 The latter seems to have the most success in improving timeliness of 
care.9 From a patient’s point of view, shortening diagnostic delay can reduce 
emotional distress in suspected cancer.10-13 Moreover, although many pa-
tients suspected of cancer eventually have a benign outcome they do share 
the distress of diagnostic evaluation.
In an effort to improve the rapidity of the diagnostic process, a two-day Rap-
id Outpatient Diagnostic Program (RODP) for patients with a radiological 
suspicion of lung cancer was implemented in the Radboud University Nijme-
gen Medical Centre (RUNMC) in 1999. As a first diagnostic step in all patients 
we implemented in this RODP both FDG-PET and contrast enhanced CT 
(FDG-PET/CT), a novel combination at that time that proved to be a superior 
imaging technique in lung cancer staging14-17 compared to either FDG-PET 
with low dose CT or CT alone. Aukema et al. have already demonstrated in a 
modest sample size that FDG-PET/CT within an RODP was feasible with good 
negative predictive value (NPV) of 92% and positive predictive value (PPV) of 
77%.18 To our knowledge, the effect of an RODP including FDG-PET/CT on 
timeliness of care has not been described yet. The aim of this study was to 
assess the diagnostic performance of FDG-PET/CT as a first-line diagnostic 
tool and the effect on timeliness of care in patients referred to our RODP 
based on an abnormal chest X-ray.
MAteriAls And Methods
Patients
A retrospective chart review was conducted in all 570 consecutive patients 
referred to the RODP between August 1999 and April 2009, after regional eth-
ics committee approval. We selected all cases where referral was based on a 
chest X-ray, to prevent bias of referring highly suspected patients and to fa-
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Multidisciplinary evaluation of PET/CT
Pulmonary function testing
Chest physician visit, physical examination, report of PET/CT results 
(first 2 patients)
Day 2 (Thursday)
Physician visit, physical examination, report of PET/CT results 
(second 2 patients)
Bronchoscopy
Report of cytology results
cilitate comparison with the usual referral pattern. On referral, outpatients 
with a radiological suspicion of lung cancer (e.g. a nodule, mass, hilar en-
largement, widened mediastinum) without clinical need for hospitalization 
or evident stage iv disease were selected by a respiratory physician to enter 
the RODP. Patients then underwent a full diagnostic workup (table 1) in two-
days comprising blood analysis, FDG-PET scanning, diagnostic CT-scan-
ning, electrocardiography, pulmonary physician consultation, pulmonary 
function testing on the first day, followed by bronchoscopy and disclosure of 
the cytology results on the second. In case of benign results on FDG-PET/CT, 
bronchoscopy was cancelled. If further diagnostic or staging procedures 
were necessary, they were performed in a regular setting outside the RODP.
fDg-Pet/Ct
All patients underwent a whole body FDG-PET. Prior to 18F-fluorodeoxyglucose 
(FDG) injection, patients fasted for at least six hours. Intake of sugar-free 
liquids was permitted. Patients were hydrated with 500 ml of water immedi-
ately prior to the procedure and 60 minutes after intravenous injection of 
approximately 250 MBq FDG (Covidien, Petten, The Netherlands) and 10 mg 
furosemide. Images were acquired from the area between the proximal fem-
ora to the base of the skull. Until September 2005, PET scans were acquired 
on an ECAT-EXACT full ring PET-scanner (Siemens/CTI, Knoxville, TN, USA) 
using three-dimensional emission for 10 min per bed position and employ-
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ing attenuation correction based on two-dimensional germanium-68 trans-
mission images for 2 min per bed position. PET scans were reconstructed 
using an iterative two-dimensional ordered subset expectation maximiza-
tion (OSEM) algorithm using two iterations, eight subsets and a three-di-
mensional Gaussian filter of 5 mm. From September 2005 onwards, PET 
scans were acquired with a hybrid PET/CT scanner (Biograph Duo, Siemens 
Medical Solutions USA, Inc.) containing a 2-slice CT scanner. A low-dose CT 
scan for localization and attenuation-correction purposes was acquired in 
the caudocranial direction. Scanning parameters included 40 mA.s (50 mA.s 
for patient weight >100 kg and 60 mA.s for >120 kg), 130 kV, 5 mm slice col-
limation, 0.8 s rotation time, and pitch of 1.5, reconstructed to 3 mm slices 
for smooth coronal representation. Low dose CT scans were acquired during 
timed unforced expiration breath-hold. For PET, a 3-dimensional whole body 
emission scan was acquired during free breathing. The acquisition time per 
bed position was 4 minutes for emission only.
A full-dose CT scan with contrast enhancement of thorax and liver for diag-
nostic purposes was acquired in all patients. Using a dual slice spiral CT 
scanner thoracic images were acquired in a craniocaudal direction after a 
delay of 40 s after intravenous contrast injection with 100ml Optiray 300 
(Covidien, Hazelwood, MO, USA) using care dose referenced at 80 mA.s with 
the following parameters, 110 kV, CTDI volume 5.36 mGy, rotation time 0.8, 
slice 3.0 mm with a pitch of 1.5 mm during a single breath hold. Scanning 
parameters for liver imaging were care dose referenced at 80 mA.s, 130 kV, 
CTDI volume 8.64 mGy, rotation time 0.8, slice 3.0 mm with a pitch of 1.5 mm 
during breath hold. A delay of 12 s was set to automatically shift to the ab-
dominal imaging.
All FDG-PET/CT images were reviewed prior to bronchoscopy in a joint-read-
ing meeting in presence of a nuclear medicine physician, a radiologist and 
pulmonary physician. If FDG uptake was present, reports were reviewed to 
determine whether extrathoracic metastases or synchronous extrathoracic 
tumours were detectable in the above defined areas scanned by diagnostic 
CT. If FDG uptake was absent, CT findings were reviewed and defined non-
malignant in case of sclerotic bone lesions, nodules with benign calcifica-
tion pattern, pleural plaques, infiltrates, or mediastinal bulging by goitre, 
mediastinal fat, or cardiomegaly.
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statistiCal analYsis
Descriptive statistics were used to summarize the demographic data col-
lected. The mean and standard deviation (SD) for normally distributed con-
tinuous variables, and median and interquartile range (IQR) for variables 
that are not normally distributed, were reported. PPV and NPV were calcu-
lated. Different delays were defined as follows: Referral delay as the time 
between referral (written or by phone) and first RODP day, diagnostic delay 
as the time between first RODP day and date of final (accurate) diagnosis, 
therapeutic delay as the time between diagnosis and start of treatment. All 
time intervals were calculated in calendar days (including weekend and hol-
idays) if both defining dates had been recorded. All data were analyzed using 
the SPSS 16.0 statistical software program (SPSS, Chicago, IL).
results
DemograPhiC Data anD CliniCal CharaCteristiCs
A flowchart of the RODP patients included in the analysis is shown in figure 
1. Of those evaluated in the RODP between August 1999 and April 2009 we 
found 565 patients with available charts, of which 386 patients were suitable 
for analysis and 184 were excluded. Referral based on abnormal radiological 
investigation other than a chest x-ray was the most frequent reason for exclu-
sion. 
Most patients were male (n=258, 66.8%) and mean age was 64.3 years (SD 
11.0). Referral was initiated by a GP in 194 patients (50.3%), the remainder 192 
by a specialist consultant. The majority of patients (n= 367, 94.0%) had an 
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, 
and 37 patients (9.6%) suffered from diabetes mellitus. Cytological or histo-
logical results are described in table 2. 
Pathology diagnosis was obtained by RODP bronchoscopy in 196 cases 
(50.8%). Other diagnostic procedures were CT-guided needle biopsy (23, 
6.0%), thoracotomy or thoracoscopic surgery (73, 18.9%), mediastinoscopy 
(24, 6.2%), EUS (10, 2.6%) or a second bronchoscopy (5, 1.3%). In 236 patients 
(61.1%) a final diagnosis of lung cancer was made, all subtypes considered 
(Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC) or 
both). Twenty seven patients (7.0%) were diagnosed with malignant pleural 
mesothelioma or pulmonary metastases of a non-pulmonary tumour. Sev-
enty eight patients (20.2%) had a certain benign diagnosis (predominantly 






570  ROPD patients
386 Available for analysis
194 Referred by GP 192  Referred by specialist
No retrievable charts: 5
Self-referral: 2
Died before completing RODP: 2
Referred after CT angiography, HRCT  
or FDG-PET: 150
No RODP diagnosis, further analysis  
futile or refused: 19
Entered RODP to confirm or exclude pulmonary 
involvement in confirmed cancer: 6
FIGURe 1    flow chart of the rodp patients
HRCT: High resolution CT-scan
infectious, post-infectious or granulomatous abnormalities). In 45 patients 
(11.7 %), no definite pathological diagnosis could be established but accord-
ing to the medical charts no malignancies were reported during a median 
24.5 months (IQR 17.0-48.5) follow up in any of them. 
Table 3 describes the clinical and pathological disease stages (according to 
the TNM619) and shows that 122 lung cancer patients (51.7%) had clinically 
advanced (stage iiib or iv) disease. 
DiagnostiC PerformanCe of fDg-Pet/Ct as a first line  
DiagnostiC tool
Performance of FDG-PET/CT was assessed in a cross table for all patients 
(table 4). For diagnosis of malignancy, sensitivity was 97.7% (95% CI 94.9-
99.1%), specificity 60.2% (50.9-68.8%), negative predictive value 92.5% (83.8-
96.9%) and positive predictive value 84.0% (79.3-87.8%). Accuracy, defined as 
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table 2    cytological or histological diagnosis of all 386 evaluable patients
NSCLC: Non-Small Cell Lung Carcinoma; BAC: Bronchoalveolar Carcinoma; NOS: not otherwise specified; 
SCLC: Small Cell Lung Carcinoma.
table 3    clinical and pathological disease stage
Patients with no pathology  confirmation before surgery were staged based on imaging and  
added to the clinical stage category.
Pathology diagnosis n (%)
Lung Cancer (all subtypes) 236 (61.1)
NSCLC 212 (54.9)
 Adenocarcinoma 96 (24.9)
 BAC 2 (0.5)
 Squamous cell carcinoma 86 (22.3)
 Large cell carcinoma NOS 12 (3.1)
 Large cell neuro-endocrine carcinoma 4 (1.0)
 Undifferentiated NSCLC 4 (1.0)
 Mixed NSCLC subtypes 8 (2.1)
SCLC 2 (0.5)
Mixed NSCLC/SCLC 22 (5.7)
Pulmonary metastasis of other cancer 23 (6.0)
Mesothelioma 4 (1.0)
Benign 78 (20.0)
 No diagnosis, benign at follow up   45 (11.7)
nsclc and sclc stage   n (%)
Clinical Stage Ia 26 (11.0)
(n= 236) Ib 31 (13.1)
  IIa 2 (0.8)
  IIb 7 (3.0)
  IIIa 46 (19.5)
  IIIb 42 (17.8)
  IV 80 (33.9)
  Double tumor 2 (0.8)
Pathological Stage Ia 24 (28.9)
(n=83) Ib 24 (28.9)
  IIa 1 (1.2)
  IIb 14 (16.9)
  IIIa 8 (9.6)
  IIIb 5 (6.0)
  IV 3 (3.6)
  Double tumor 3 (3.6)
pNx (incomplete pN stage)  1 (1.2)
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table 4    patient numbers of fdg-peT/cT result and final diagnosis of malignancy
table 5    cT characteristics in patients with cT-confirmed benign definite findings 
total grouP  386
Definite benign CT findings 32 (8.3)
 CT without abnormalities 13 (3.4)
 Clearly benign lesion on CT alone 19 (4.9)
  Sclerotic bone lesion 7
  Calcified nodule 3
  Pleural plaque 3
  Post-infectious infiltrate 3
  Mediastinal mass (goitre, fat, cardiomegaly) 3
 Malignant Benign total
PET/CT Positive 257 49 306
PET/CT Negative 6 74 80
Total 263 123 386
the proportion of true results, was 85.8% (81.4-90.0%). Performances of hy-
brid FDG-PET/CT and separate FDG-PET and CT (before and after September 
2005 respectively) were not statistically different.
We found 19 cases (4.9%) where suspected lesions showed radiologically be-
nign anomalies on CT scan and were FDG-PET negative (specified in table 5). 
In another 13 cases (3.1%) no abnormalities were found at all on FDG-PET or 
CT. In contrast, FDG-PET showed metastatic disease in 26 (6.7%) patients 
(10.8% in the lung cancer patient sample) and a synchronous tumour of oth-
er cancer type in 9 patients (2.3% of the total patient group), outside the 
volume scanned by diagnostic CT. Finally, there were 6 false negative cases, 
all with different histology: Adenocarcinoma (7mm), bronchoalveolar carci-
noma (5mm), squamous cell carcinoma (29mm), malignant pleural mesothe-
lioma (pleural fluid only), pulmonary metastasis of ovarian cancer (multiple 
nodules, largest 12 mm) and adenoid cystic carcinoma (multiple nodules 
ranging 15-23 mm).
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DelaYs
For the total patient group, the median referral delay was 7 days (IQR 5-10), 
and median diagnostic delay 1 day (IQR 1-15). For patients ultimately diag-
nosed with lung cancer (NSCLC and SCLC), median referral delay was also 7 
days (IQR 5-9), median diagnostic delay 2 days (IQR 1-17), median therapeutic 
delay 19 days (IQR 7-28), The median interval between RODP and all thera-
pies spanned 25 days (IQR 18 -39): 23 days (IQR 18-32) for surgery, 27 days (IQR 
14-41) for chemotherapy and 28 days (IQR 20-50) for radiotherapy. 
discussion
This is so far the largest study evaluating FDG-PET/CT as a frontline diagnos-
tic tool in an RODP setting for suspected lung cancer. We demonstrate that 
an RODP integrating FDG-PET/CT provides not only excellent diagnostic per-
formance in detecting lung cancer in patients referred with an abnormal 
chest X-ray, but also minimizes diagnostic delay. RODPs have shown to suc-
cessfully reduce the diagnostic delay in 2 other studies that evaluated a two 
stop service in suspected lung cancer and report a presentation to surgery 
delay of 5 weeks7 and presentation to start of any treatment delay of 3 weeks,8 
respectively. These studies were however performed in an era when FDG-PET 
was not yet, in contrast with today, a standard imaging tool in the diagnostic 
work-up of lung cancer, with superior imaging capabilities.14-17 One would 
expect the combination of an RODP with FDG-PET/CT to improve the overall 
diagnostic work-up quality in patients with suspected lung cancer. Our 
results confirm these expectations: with the demonstrated schedule of 
our RODP, the median time to establish a diagnosis was only one day, and 
treatment was initiated after a median 25 days. Both these diagnostic and 
therapeutic delays were shorter than the median 7-37 days for diagnos-
tic2,5,20-28 and 31-104 days for therapeutic delay4,23,29,30 reported by others with-
out an RODP. 
Besides timeliness, our RODP including FDG-PET/CT had an excellent diag-
nostic performance with high sensitivity in diagnosing malignancy (97.7%). 
We herewith confirm the earlier results described by Aukema et al. showing 
good performance of RODP using FDG-PET/CT in diagnosing pulmonary 
malignancy. In 114 patients referred with an abnormal chest X-ray, they dem-
onstrated similar sensitivity, specificity and accuracy for diagnosing malig-
nancy (97%, 56% and 90%, respectively) despite a higher pre-test probability 
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of lung cancer (75% versus 61% in the present study). This difference might 
be explained by a different referral pattern to their centre with a specialized 
reference oncology status.18 Specificity was relatively lower in both Aukema’s 
and our study (56 and 60 %, respectively) and can be explained by the inclu-
sion of patients on the basis of an abnormal chest X-ray: Studies evaluating 
the accuracy of FGD-PET/CT usually include patients with solitary pulmo-
nary nodules on a CT scan, inherently lowering the probability of infectious 
or inflammatory disease compared to our selection of patients. FDG-PET/CT 
then demonstrates equal median sensitivity (97.0%, range 83-100%) but 
higher specificity (77.8%).31 
The downside of incorporating both FDG-PET and a diagnostic CT in an 
RODP setting as a first line diagnostic tool for all patients referred with an 
abnormal chest X-ray is that retrospectively in some cases additional imag-
ing with FDG-PET to exclude malignancy might not have been required: In 
32 patients (8.3%) malignancy might have been excluded on CT alone as the 
lesions showed typical benign characteristics. This number is in line with 
the study by Aukema et al.18 reporting around 10% abnormalities that could 
have been judged benign on CT alone (asbestos related benign pleural ab-
normality and residual abnormality after inflammation). However whether 
there is actually ‘diagnostic overuse’ in these cases cannot be judged retro-
spectively, as in both Aukema’s and our study FDG-PET and CT images were 
jointly read. In contrast, in 35 patients (9.1%) FDG-PET/CT had significant 
added value as it detected metastases or synchronous tumours outside the 
chest that would not have been detected by CT alone. This result is in line 
with prior prospective studies detecting distant metastases in 6-18% of po-
tentially curable lung cancer patients.15,16, 32-34 FDG-PET/CT furthermore cor-
rectly suggested other than lung cancers in 9 RODP patients (2.3%) which is 
in line with other studies detecting unexpected synchronous tumors in 1.1-
3.3%.35,36 Whether detecting unexpected metastatic disease and synchronous 
tumours by FDG-PET/CT in the RODP counterbalances performing FDG-PET 
in case of radiologically benign lesions, cannot be answered by our study; 
this should involve comparison of other factors such as cost-effectiveness37 
and the prevention of futile thoracotomies.15,35,38 Furthermore there might be 
a benefit of an RODP in quickly ruling out the possibility of cancer and reduc-
ing distress levels13 that were raised by the chest X-ray. To address these is-
sues, we have performed the multicenter PENELOPE study (Pulmonary Eval-
uation of NEoplastic Lesions in Outpatients and Psychological Effects) 
evaluating distress and quality of life in suspected lung cancer patients dur-
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ing and after their RODP compared to regular stepwise outpatient evalua-
tion. We expect to publish results in 2013. 
conclusion
Our findings add to the limited knowledge available on rapid outpatient pro-
grams, despite growing interest on performance of these programs and pos-
sible effects on patient distress. Our study shows that in patients referred 
with an abnormal chest X-ray, an RODP integrating FDG-PET/CT provides 
excellent diagnostic performance in detecting lung cancer with minimized 
diagnostic delay.
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ABstrAct 
oBjeCtIve: To perform a systematic review of articles published in the last 
25 years on prevalence and course of distress and quality of life surrounding 
the diagnostic process of suspected cancer, and the influence of rapid diag-
nostic programs.
Methods: Twenty-three articles were identified via Pubmed, PsycINFO, and 
reference lists of articles. Except for three randomized clinical trials and one 
case control study all studies were uncontrolled cohort studies.
results: Most studies involved patients with suspected breast cancer 
and therefore had a sex selection bias. Four studies on the effect of rapid 
outpatient diagnostic programs were found. Studies showed very high prev-
alence of anxiety, decreasing in case of a benign diagnosis but increasing or 
sustaining in patients waiting for results or after cancer diagnosis though 
not significantly more in rapid programs. Quality of life was low and showed 
varying patterns.
ConClusIons: Distress in the diagnostic phase of cancer is a major prob-
lem and the rapid decrease of anxiety in patients eventually not diagnosed 
with cancer suggests a benefit of rapid diagnostic programs. The available 
evidence however is limited and shows some inconsistencies. Studies differ 
in subjects, objective and are limited by quality and quantity. Conflicting 
results prohibit a conclusion on patients ultimately diagnosed with cancer. 
introduction
Many cancer patients experience emotional distress in the course of their 
disease. In the oncology setting, emotional distress can be defined as an 
adjustment disorder and is most frequently characterized by anxiety or de-
pression.1 The prevalence of emotional distress among cancer patients, with 
numbers reported of a fifth to even half of all patients,1-10 combined with high 
incidence rates of cancer in the western world,11,12 suggest emotional distress 
in cancer patients is an ubiquitous problem. And indeed, emotional distress 
is a well-studied subject in cancer research; however, the emotional impact 
of the diagnostic phase is overlooked.
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Receiving a diagnosis of cancer is a major cause of distress.13,14 It has even 
been included as a potential trauma in the DSM-IV.15 Authors report higher 
levels of distress directly after diagnosis compared to later in the course of 
the disease.6,16-18 However, there are surprisingly few studies on emotional 
distress in the diagnostic phase itself although cancer patients, as well as 
large groups of patients eventually not diagnosed with cancer, go through 
several more or less invasive diagnostic procedures during a period of uncer-
tainty. Cancer also affects Quality of life (QoL) which is a multidimensional 
composition of different contributing factors. It stands without reason that 
QoL has become a key factor in oncology; however as abundant literature 
assessing QoL in the therapeutic or post-therapeutic phase is, the more 
scarce it is around diagnosis. 
The emotional impact of the diagnostic phase requires more emphasis, for 
the following three reasons. Firstly, as stated above, prevalence of emotional 
distress in cancer patients during the course of their disease is high, indicat-
ing this is a population at risk. Secondly, as anxiety, depression and QoL can 
be improved by psychosocial interventions in cancer patients,19 early detec-
tion may be beneficial. Thirdly, the diagnostic phase can be substantially 
shortened by rapid diagnostic pathways (one- or two-stop diagnostic ser-
vices) that have been implemented in the recent years, resulting in a shorter 
period of uncertainty and improved patient satisfaction. These pathways 
have been clinically or economically evaluated for different cancer types 
however information on the effect of these pathways on distress is limited 
and restricted to breast cancer patients.20 However they also exist for other 
cancer types, mostly lung cancer.21-23 Suspected lung cancer patients might 
be a unique subset, as lung cancer is the second most frequent malignancy 
with the highest death rate in the western world, requires in most cases mul-
tiple, sometimes quite invasive staging techniques and lung cancer patients 
are also known to have a higher distress prevalence during the course of 
their disease than other cancer types.2 
In this paper we aim to establish the effect of this diagnostic phase on anxi-
ety, depression and QoL and the effect of shortening diagnostic procedures 
to a one- or two-stop pathway. The following research questions are the ob-
jective of the systematic review:
• What are pre-diagnostic levels of anxiety in patients with suspicion of can-
cer?
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• What are the effects of receiving a benign or malignant diagnosis on short-
term distress and QoL? 
• What are the effects of a rapid diagnostic pathway on emotional distress 
and QoL for different cancer types?
Methods
searCh strategY
We searched the Cochrane database of systematic reviews, Pubmed and 
Psyc INFO from 1984 up to February 2009. We used the following keywords 
(Mesh-terms): Diagnosis, Neoplasm/psychology, anxiety/diagnosis, depres-
sion/diagnosis, stress, psychological, psychological stress, quality of life. 
The searches were limited to humans, all adult (over 19 years old) and Eng-
lish language. We checked all titles and abstracts. Full text copies were ob-
tained when studies had possible relevance. Following the keyword search, 
we carried out a backward search by examining reference lists of all papers 
obtained. We reviewed all titles and abstracts for the following inclusion 
criteria: Patients with suspicion of cancer who were scheduled to undergo at 
least one invasive diagnostic procedure to obtain a cytological or histologi-
cal diagnosis, use of validated or at least standardized measures of anxiety, 
depression or QoL, use of these measures before diagnosis prospectively, 
and in case of follow-up to do so within six weeks. To make a distinction 
between short and long term with respect to the diagnosis of cancer, we had 
defined the period of six weeks after diagnosis as short term. This definition 
is arbitrary, but chosen bearing in mind the acute stress disorder that re-
stricts the period of acute distress symptoms to four weeks;15 acute distress 
symptoms of the procedures and receiving the diagnosis will supposedly 
have subsided after six weeks. Moreover, distress levels after this period 
might be correlated with therapy or disease progression. Studies examining 
emotional distress around cancer screening procedures or cancer surgery 
and papers on the influence of cancer awareness were excluded, as were ab-
stracts, case studies, small pilot studies, letters and editorials.
extraCteD information
The following information was extracted from each study: report informa-
tion (authors, year of study, journal name, type of cancer), study design, 
sample size, measures and questionnaires used, time intervals between 
measures or diagnosis, major findings and limitations with respect to an-
swering our questions.
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                CANCER TyPES





                STUDy TyPES
2 RCT, 1 CC, 13 PC                     1 PC                     1 PC                     2 PC                     2 PC, 1 RPP
FIGURe 1    overview of numbers and types of studies selected for review 
RCT: randomized clinical trial, CC: case control study, PC: prospective cohort study,  
RPP: Randomized prospective pilot study. 
results
searCh result
Out of a total of 1846 articles, eventually 23 were eligible for review (see figure 
1); 19 articles reported on anxiety and 7 on QoL or both. Since we had per-
formed a broad search for which only rather non-specific keywords could be 
used, most articles were excluded; most frequent reasons for exclusion were 
studies being limited to the therapeutic rather than the diagnostic phase, 
measuring distress and QoL around surgical or other therapeutic proce-
dures, and not including a pre-diagnostic measurement. Among the 23 arti-
cles finally reviewed, there were three articles reporting pre-diagnostic levels 
only.24-26 All other articles also reported follow-up levels; in five studies these 
exceeded six weeks.27-31 Finally, one article did not report absolute values but 
changes over time.22
Pre DiagnostiC levels of anxietY
Pre-diagnostic levels of anxiety were reported in 19 studies and are presented 
in Table 1. Different measures for anxiety were used in these studies, most 
frequently the HADS (Hospital Anxiety and Depression Scale),32 a 14-item 
questionnaire consisting of two subscales of anxiety and depression. Items 
are rated on a four-point scale, rendering a maximum total score of 21. On 
either subscale, scores of 0-7 are considered normal; scores of ≥11 are con-
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sidered a significant ‘case’ of psychosocial morbidity, scores of 8-10 are con-
sidered ‘borderline’ and indicate potential clinical anxiety or depression. 
Suspected breast cancer patients had scores of ≥8 in 46-73% of cases,28,33-35 
Reported scores of ≥11 were 28-48%.25,35,36 Mean HADS anxiety scores ranged 
from 7.7 to 10.6.28,33,34 The study by Al-Shakli et al. on suspected malignant 
melanoma patients showed potential clinical anxiety in 27% of women (19% 
borderline plus 6% case anxiety) and 10% of men (6% borderline plus 4% 
case anxiety).37 The one study on suspected lung cancer patients had 6% bor-
derline and 10% case anxiety, with a mean anxiety score of 4.6.27 In studies 
using the STAI (State-Trait Anxiety Inventory),38 which is a 40-item question-
naire designed to measure state and trait aspects of anxiety adding up to a 
scale range from 20 to 80 (higher scores indicate more anxiety, and above a 
cut-off score of 44 is considered high anxiety), suspected breast cancer pa-
tients had mean state anxiety scores between 40.1 and 60.0.25,31,33,35,39,40 
Remarkably, some patients with breast cancer were more anxious at baseline 
than patients with benign disease.31,40 Japanese ovarian carcinoma patients 
had a similarly high mean score of 49.5, with 77.8% of patients above the 42 
point cut-off (which was adapted for Japanese women).41 In this particular 
study, an additional neuropsychiatric interview diagnosed 33% of suspected 
patients with an adjustment disorder. Again, patients in the study on malig-
nant melanoma, that used a six item short form of the STAI (STAI-SSF) had 
lower mean scores of 10.6 in men and 12.7 in women.37 
The two studies that used the POMS (Profile of Mood States) focused on pa-
tient factors that influence distress around breast and prostate biopsy; un-
fortunately the pre-biopsy results could not be compared to those from the 
other studies since no normative data exist on the scales that were used.42,43
Two breast cancer studies used the BSI (Brief Symptom Inventory),44 a 53 
items questionnaire designed to asses psychological symptom status, with 
higher scores indicating higher levels of distress. Moderate to high pre-diag-
nostic anxiety was reported (27.5 on the total scale) but substantially more in 
the group of patients that later would receive a cancer diagnosis – a phenom-
enon the authors could not explain.45 Northouse et al. used the GSI (Global 
Severity Index, a BSI subscale) and similarly reported a score of 0.5 to 0.57, 
where 0.3 is the mean score of a normal population.26
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table 1    data extracted from articles found on anxiety around diagnosis;  
effect of a rapid diagnosis in upper 3 studies 
first  Design CanCer samPle interval measures Pre-DiagnostiC Distress Change  Distress Change  Comments
author  tYPe    anxietY benign CanCer
       Diagnosis Diagnosis 
Harcourt 36 RCT Breast 583 females 6 days  VAS HADS-A ≥11: 28% RP: ‘case’ anxiety 29.0%→ 11,3%*  RP: ‘case’ anxiety 22.5%→53.7% Only 55 cancer patients (9%), 
     HADS  RG: ‘case’ anxiety 27.8%→ 19.5%# RG: ‘case’ anxiety 29.6%→ 41.4%$ possible perception of cues
       RP: HADS-D 3.50→ 2.32  RP: HADS-D 3.90→ 5.37@ from surgeon on future result
       RG: HADS-D 3.45→ 3.04$ RG: HADS-D 3.3.63→ 3.83# 
Ubhi 35 PC Breast 102 females RP: 0 days STAI-SSF HADS-A≥8<11: 23.8% RP: STAI 52.44→ 37.95 RP: STAI 44.67→ 51.85 No comparison of all patients
    RG: 1 week HADS HADS-A≥11: 36.1% RG: STAI 47.35→ 40.47 RG: STAI 44.44→ 53.81$ after 1 week, only 16 cancer 
       STAI-SSF: 49.0   patients (16%)
Dey 33 RCT Breast 478 females RP: 0 days STAI-SS HADS-A≥8: 58%  Benign and cancer patients (one day) Benign and cancer patients Only 10 patients (3%) with
    RG: 1 week  mean 9.1  (3 weeks) malignant melanoma, no comparison
    Assessments:  HADS-A RP: STAI 48.4 RP: STAI 48.1→ 34.5* RP: HADS-A 8.9→ 7.3 of melanoma and benign cases after
    1 day and   RG: STAI 47.6 RG: STAI 47.2→ 39.8# RG: HADS-A 8.8→ 7.4$ histological diagnosis, RP only for
    3 weeks     benign cases
Al-Shakli 37 PC Malignant 195 females 0 days (clinically HADS HADS-A≥8:  Clinically benign:   STAI-SSF 14.4→ 16.0§ pre→ post- Only 10 patients (3%) with malignant
  melanoma 126 males  benign)  women 27%, men 10% STAI-SSF 11.49→ 8.88* clinical→ 10.4* post-histological melanoma, no comparison of
    1 week (biopsy) STAI-SSF STAI-SSF women 12.7 Biopsy: STAI-SSF same day 12.73→    melanoma and benign cases after
    17 days (melanoma)  men 10.6 13.91§# later day 12.89→ 13.79§#  histological diagnosis, RP only
         for benign cases
Lampic 34 PC Breast 509 females 0-15 days HADS HADS-A ≥8: 46 %  normal: HADS-A 8.0→ 4.0* Significantly more anxiety when Variable interval, no detailed inform-
      Mean HADS-A: 7.7 cyst: HADS-A 6.8→ 2.7* awaiting possible cancer diag- ation on statistical significance of
        nosis or surgery compared to changes within groups in case of
        immediate benign outcome cancer, only 44 cancer patients (7%)
Liao 40 PC Breast 127 females Average 8.7 days  STAI-SS STAI-SS all: 60.0 STAI-SS  56.93→ 58.89§→ 45.40* STAI-SS  62.02→ 62.24§→ 62.41§ Nonverbal cues might cause higher
    (range 2-31)     anxiety levels, variable interval, 
    post consultation→    benign: 56.93   scores of Taiwanese probably higher 
    before biopsy→     than of western women
    diagnosis  cancer: 62.02@
Stanton 43 PC Breast 117 females Average 7 days  POMS POMS tension 11.24 POMS tension 11.24→ 4.59* POMS tension 11.24→ 12.97* Part of the post diagnosis distress
    (diagnosis),    (cancer) total   attributed to upcoming surgery.
    18 days (surgical   POMNEG 39.8   Only 30 cancer patients (20% of
    breast biopsy)     total group) completed all measures
Dekeyser 45 PC Breast 35 females 7-10 days and BSI BSI all: 27.5 BSI 19.07→ 13.4 BSI 54.2→ 54.7 No significance level reported for
    14-20 days ASDS benign: 19.07   sequential anxiety changes, power
      cancer: 54.2@   analysis proved study too small,
         actual time intervals not reported, 
         high pre- diagnostic anxiety in
         eventual cancer unexplained
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table 1    data extracted from articles found on anxiety around diagnosis;  
effect of a rapid diagnosis in upper 3 studies 
Significance levels if given in articles:
* p< 0.05 before compared to after,  # P< 0.05 rapid compared to regular,  
@ p< 0,05 cancer compared to benign, § non-significant before compared to after,  
$ non-significant rapid compared to regular.
>>> continue on next page
first  Design CanCer samPle interval measures Pre-DiagnostiC Distress Change  Distress Change  Comments
author  tYPe    anxietY benign CanCer
       Diagnosis Diagnosis 
Harcourt 36 RCT Breast 583 females 6 days  VAS HADS-A ≥11: 28% RP: ‘case’ anxiety 29.0%→ 11,3%*  RP: ‘case’ anxiety 22.5%→53.7% Only 55 cancer patients (9%), 
     HADS  RG: ‘case’ anxiety 27.8%→ 19.5%# RG: ‘case’ anxiety 29.6%→ 41.4%$ possible perception of cues
       RP: HADS-D 3.50→ 2.32  RP: HADS-D 3.90→ 5.37@ from surgeon on future result
       RG: HADS-D 3.45→ 3.04$ RG: HADS-D 3.3.63→ 3.83# 
Ubhi 35 PC Breast 102 females RP: 0 days STAI-SSF HADS-A≥8<11: 23.8% RP: STAI 52.44→ 37.95 RP: STAI 44.67→ 51.85 No comparison of all patients
    RG: 1 week HADS HADS-A≥11: 36.1% RG: STAI 47.35→ 40.47 RG: STAI 44.44→ 53.81$ after 1 week, only 16 cancer 
       STAI-SSF: 49.0   patients (16%)
Dey 33 RCT Breast 478 females RP: 0 days STAI-SS HADS-A≥8: 58%  Benign and cancer patients (one day) Benign and cancer patients Only 10 patients (3%) with
    RG: 1 week  mean 9.1  (3 weeks) malignant melanoma, no comparison
    Assessments:  HADS-A RP: STAI 48.4 RP: STAI 48.1→ 34.5* RP: HADS-A 8.9→ 7.3 of melanoma and benign cases after
    1 day and   RG: STAI 47.6 RG: STAI 47.2→ 39.8# RG: HADS-A 8.8→ 7.4$ histological diagnosis, RP only for
    3 weeks     benign cases
Al-Shakli 37 PC Malignant 195 females 0 days (clinically HADS HADS-A≥8:  Clinically benign:   STAI-SSF 14.4→ 16.0§ pre→ post- Only 10 patients (3%) with malignant
  melanoma 126 males  benign)  women 27%, men 10% STAI-SSF 11.49→ 8.88* clinical→ 10.4* post-histological melanoma, no comparison of
    1 week (biopsy) STAI-SSF STAI-SSF women 12.7 Biopsy: STAI-SSF same day 12.73→    melanoma and benign cases after
    17 days (melanoma)  men 10.6 13.91§# later day 12.89→ 13.79§#  histological diagnosis, RP only
         for benign cases
Lampic 34 PC Breast 509 females 0-15 days HADS HADS-A ≥8: 46 %  normal: HADS-A 8.0→ 4.0* Significantly more anxiety when Variable interval, no detailed inform-
      Mean HADS-A: 7.7 cyst: HADS-A 6.8→ 2.7* awaiting possible cancer diag- ation on statistical significance of
        nosis or surgery compared to changes within groups in case of
        immediate benign outcome cancer, only 44 cancer patients (7%)
Liao 40 PC Breast 127 females Average 8.7 days  STAI-SS STAI-SS all: 60.0 STAI-SS  56.93→ 58.89§→ 45.40* STAI-SS  62.02→ 62.24§→ 62.41§ Nonverbal cues might cause higher
    (range 2-31)     anxiety levels, variable interval, 
    post consultation→    benign: 56.93   scores of Taiwanese probably higher 
    before biopsy→     than of western women
    diagnosis  cancer: 62.02@
Stanton 43 PC Breast 117 females Average 7 days  POMS POMS tension 11.24 POMS tension 11.24→ 4.59* POMS tension 11.24→ 12.97* Part of the post diagnosis distress
    (diagnosis),    (cancer) total   attributed to upcoming surgery.
    18 days (surgical   POMNEG 39.8   Only 30 cancer patients (20% of
    breast biopsy)     total group) completed all measures
Dekeyser 45 PC Breast 35 females 7-10 days and BSI BSI all: 27.5 BSI 19.07→ 13.4 BSI 54.2→ 54.7 No significance level reported for
    14-20 days ASDS benign: 19.07   sequential anxiety changes, power
      cancer: 54.2@   analysis proved study too small,
         actual time intervals not reported, 
         high pre- diagnostic anxiety in
         eventual cancer unexplained
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table 1 seqUel  lower 7 studies with pre-diagnostic assessment only. 
first  Design CanCer samPle interval measures Pre-DiagnostiC Distress Change  Distress Change  Comments
author  tYPe    anxietY benign CanCer
       Diagnosis Diagnosis 
Witek-36 C-PC Breast 121 females 1 day  PSS, POMS Benign: POMS tension  POMS tension (but not STAI)  POMS tension and STAI Comparison with control group, 
Januse k    1 month STAI-SS and STAI higher than still higher than controls higher than controls but not exact levels or changes
      cancer or controls.    reported. Variable interval and not 
      Cancer: no difference    exactly reported
Sukegawa41 PC Ovary 27 females 7-14 days STAI-SS STAI all: 49.5, STAI 49.1→ 31.7* STAI 50.1→ 43.2* Small sample, probably pre-surgery
     MINI cancer 50.1   distress affecting first measure-
      benign 49.1   ment, exact interval variable and 
         not reported
Scott 39 PC Breast 85 females  6-8 weeks STAI-SS STAI 48.7 STAI 48.7→ 33* - Only patients with benign results,
   (benign)      exact interval variable and not
         reported
Perczek 39 PC Prostate 101 males  2 weeks POMS POMS distress score 0.68 POMS distress 0.72→ 0.62 POMS distress 0.61→ 0.79 Study aim was role of optimism and
       Significant group x time interaction Significant group x time interaction coping, not distress before and
         after diagnosis, no comment on
         changes of distress levels found
Montazeri39 PC Breast 168 females  - HADS HADS-A≥8<11: 25% - - Only cancer patients
   (cancer)   HADS-A≥11: 48%
      Mean HADS-A:10.6
Montazeri27 PC Lung 77 males - HADS HADS-A≥8<11: 6% - - Possible bias as part of study sample
   52 females,   HADS-A≥11: 10%   might have known diagnosis,
   (cancer)   Mean HADS-A: 4.6   only cancer patients
Van der PC Breast 202 females,  - STAI-SS STAI all: 44.3. - - Aim of study was determine in-
Steeg 31   (cancer)   cancer 49.5   fluence of personality traits in QoL
      benign 40.1@
Madden 25 RCT Breast 50 females - STAI-SS STAI 44.8 - - Aim of study was effect of 
         preparatory booklet    
Nosarti 30 PC Breast 87 females - GHQ-12 GHQ-12 case 33.8% - - Aim of study was course and risk
   (cancer)      factors of psychological morbidity
         during first year, only cancer patients
Chen 24 PC Breast 121 females - GHQ-12 GHQ-12 case 37.5% - - Actual diagnostic procedure
         before assessment
Northouse 26 PC Breast 300 females,  - BSI Women overall  - - - 
   265 husbands   distress: 0.57
      Husbands: 0.37
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table 1 seqUel  lower 7 studies with pre-diagnostic assessment only. Significance levels if given in articles:
* p< 0.05 before compared to after,  # P< 0.05 rapid compared to regular,  
@ p< 0,05 cancer compared to benign, § non-significant before compared to after,  
$ non-significant rapid compared to regular.
first  Design CanCer samPle interval measures Pre-DiagnostiC Distress Change  Distress Change  Comments
author  tYPe    anxietY benign CanCer
       Diagnosis Diagnosis 
Witek-36 C-PC Breast 121 females 1 day  PSS, POMS Benign: POMS tension  POMS tension (but not STAI)  POMS tension and STAI Comparison with control group, 
Januse k    1 month STAI-SS and STAI higher than still higher than controls higher than controls but not exact levels or changes
      cancer or controls.    reported. Variable interval and not 
      Cancer: no difference    exactly reported
Sukegawa41 PC Ovary 27 females 7-14 days STAI-SS STAI all: 49.5, STAI 49.1→ 31.7* STAI 50.1→ 43.2* Small sample, probably pre-surgery
     MINI cancer 50.1   distress affecting first measure-
      benign 49.1   ment, exact interval variable and 
         not reported
Scott 39 PC Breast 85 females  6-8 weeks STAI-SS STAI 48.7 STAI 48.7→ 33* - Only patients with benign results,
   (benign)      exact interval variable and not
         reported
Perczek 39 PC Prostate 101 males  2 weeks POMS POMS distress score 0.68 POMS distress 0.72→ 0.62 POMS distress 0.61→ 0.79 Study aim was role of optimism and
       Significant group x time interaction Significant group x time interaction coping, not distress before and
         after diagnosis, no comment on
         changes of distress levels found
Montazeri39 PC Breast 168 females  - HADS HADS-A≥8<11: 25% - - Only cancer patients
   (cancer)   HADS-A≥11: 48%
      Mean HADS-A:10.6
Montazeri27 PC Lung 77 males - HADS HADS-A≥8<11: 6% - - Possible bias as part of study sample
   52 females,   HADS-A≥11: 10%   might have known diagnosis,
   (cancer)   Mean HADS-A: 4.6   only cancer patients
Van der PC Breast 202 females,  - STAI-SS STAI all: 44.3. - - Aim of study was determine in-
Steeg 31   (cancer)   cancer 49.5   fluence of personality traits in QoL
      benign 40.1@
Madden 25 RCT Breast 50 females - STAI-SS STAI 44.8 - - Aim of study was effect of 
         preparatory booklet    
Nosarti 30 PC Breast 87 females - GHQ-12 GHQ-12 case 33.8% - - Aim of study was course and risk
   (cancer)      factors of psychological morbidity
         during first year, only cancer patients
Chen 24 PC Breast 121 females - GHQ-12 GHQ-12 case 37.5% - - Actual diagnostic procedure
         before assessment
Northouse 26 PC Breast 300 females,  - BSI Women overall  - - - 
   265 husbands   distress: 0.57
      Husbands: 0.37
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artiCle Design CanCer samPle interval measures Pre-DiagnostiC Qol Change Qol Change Comments
referenCe  tYPe    Qol benign CanCer
       Diagnosis Diagnosis 
Harcourt 36 RCT Breast 583 6 days  EORTC General QoL RP: improvement  RP: significant worsening See table 1. Pre-diagnostic
    females QLQ-C30 (GHS) 64.3-69.3 on several subscales#,  of several subscales#, QoL only reported
       general QoL 69.3→ 74.8# general QoL 68.1→ 57.1@  for different groups. 
        RG: 64.3→65.6§ After 8 weeks groups were
       RG: 67.9→ 70.0#  comparable on all measures
Murray 22  RPP Lung 55 6 weeks EORTC - - RP: worse role, social, Study aim was not primarily 
     QLQ-C30   financial functioning#,  QoL, exact data not reported,
        other dimensions only cancer patients were
        unchanged followed, twice as many
         patients had started chemotherapy  
         in RP, unknown sex of sample 
         analyzed
Al-Shakli 37  PC Malignant See See EORTC All: GHS 80.0 - RG: (all melanoma)    See table 1
  melanoma table 1 table 1 QLQ-C30 Melanoma:82.5  GHS 82.5→ 50.0*, 
        EF 75.3→ 50.8*
Van der PC Breast 202 females 1, 3,  WHOQOL-100 Benign: Overall Non-significant Non-significant  See table 1. Exact QoL
Steeg 31   (cancer) 6  months  QoL 15.0   change not reported.
      Cancer: 15.6@ 
Montazeri 29 PC Breast 167 female 3,  EORTC QLQ- Global QoL 59.2  - - Only cancer patients included.
   (cancer) 18 months C30 QLQ-BR23
Lheureux 49 PC Lung 61 males Mean 22.4 EORTC-QLQ- Global QoL 55.2 - Global QoL no significant  Only cancer patients were 
   9 females   C30 QLQ-LC13   change, deterioration of   followed, all patients were 
        most functioning scales and hospitalized, time interval variable
        arm pain
Ishihara 51  PC Prostate 141 males ≤6 weeks MOS-SF-36  SF-36 GH/MH:  GH 56→ 58.4§ GH/MH§ for all SF-36 might lack
     UCLA-PCI 50-59 years 64.2/67.6 MH 64.2→ 63.6§ different disease stages sensitivity in detecting
      60-69 years 60.2/64.6   changes. Results reported
      70+ years 56.2 /65.1   by age group only, 
      Only MH lower than    50-59 years group
      Japanese norm in    was small (n=11)
      60-69 years group 
   
table 2   data extracted from articles found on Qol around diagnosis; effect of a 
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Nosarti et al30 found ‘cases’, indicating potential clinical significant psycho-
logical distress, in 34% of patients with suspected breast cancer using the 
GHQ-12 (General Health Questionnaire – 12 item version) similar to the 
37.5% of symptomatic breast lesion patients being probable cases in the 
study by Chen et al.24
effeCts of reCeiving a benign or malignant Diagnosis on 
short-term Distress 
Detailed results and significance levels if reported are presented in Table 1. 
Patients receiving a benign diagnosis showed significant decreases in anxi-
ety in all studies reviewed irrespective of cancer type,34-73,39-42,45 except for the 
breast cancer study by Witek et al. in which anxiety levels were not analyzed 
as repeated measures; no difference was found compared to cancer patients, 
but significantly higher anxiety levels in all patients when compared to nor-
mal controls.46 
Women eventually diagnosed with breast cancer had either increased34-36,43 or 
sustained40 anxiety levels; however increases were only reported to be statis-
tically significant in one study.43 Increased anxiety was also reported in pros-
tate cancer patients.42 On the other hand, in case of melanoma37 or ovarian 
cancer41 lower anxiety levels after diagnosis were found. 
Short term depression was only reported in three breast cancer studies, one 
of which was a rapid pathway study in which depression scores after a cancer 
diagnosis in the one stop system were higher than in the two stop system but 
not for patients with benign results.36 The other two studies reported a de-
crease in depression scores after diagnosis in cancer patients34 or an increase, 
but also a decrease again after surgery.43
effeCts of reCeiving a benign or malignant Diagnosis on 
short-term QualitY of life
We found six studies assessing QoL around a cancer diagnosis with a before-
and-after comparison and one with a before measure only,47 presented in 
table 3. Suspected cancer patients scored much lower pre-diagnostic general 
QoL levels than compared to the random normal reference,48 and suspected 
lung cancer patients scored worst.49 Remarkably, one of three studies on sus-
pected breast cancer patients also found lower values compared to general 
breast cancer patients.29 For suspected lung and prostate cancer patients the 
reported pre-diagnostic values were somewhat lower than reference lung or 
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prostate cancer patients’ values.47,49,50 Surprisingly, suspected melanoma pa-
tients QoL levels exceeded both normal and melanoma patients’ values.37 
With respect to short term (within six weeks) effects on QoL, 3 studies showed 
decreases in several aspects of QoL in patients diagnosed with either breast, 
skin or lung cancer.36,37,49 Prostate cancer patients50 and patients in one breast 
cancer study31 showed no significant changes before and after diagnosis in 
patients with both malignant and benign outcomes.
effeCts of a sPeeDier DiagnostiC PathwaY on emotional  
Distress anD QualitY of life
On the specific effect of rapid diagnostic evaluation on emotional distress we 
found three studies of suspected breast cancer patients,33,35,36 presented in 
the top box of table 1. We found one study on QoL in suspected lung cancer22 
presented in table 2. We found no reports on depression in cancer patients 
in the rapid setting.
Numbers of patients, eventually receiving a cancer diagnosis were relatively 
small in all studies. Dey et al.33 found a significantly larger reduction of anx-
iety after 24 hours in one-stop evaluation, compared to two-stop evaluation 
in which patients were still awaiting results. This difference disappeared af-
ter three weeks. In both other breast cancer studies patients who were given 
benign results in the rapid systems showed significantly less anxiety after 
one week than those still waiting for results (in regular or delayed systems), 
and in the study by Harcourt also a significant decrease in depression.36 In 
contrast to the others, Ubhi et al.35 compared absolute changes in anxiety 
scores after immediate or delayed communication of cytology results and 
found that immediate communication of a benign outcome resulted in a 
greater reduction of anxiety than when this was done one week later. For 
patients with cancer there was an equal increase irrespective of communica-
tion type. The last study in this category by Harcourt et al.36 showed an in-
crease in anxiety in patients being diagnosed with malignant disease, though 
not significantly more in the one stop patients than in those still waiting for 
results. Anxiety differences between one-stop and two-stop pathways disap-
peared after two months in this study, however one-stop patients then had 
unexplained significantly higher though subclinical (mean HADS-D 5.47) 
depression rates that had increased 1.54 clinically debatable points. This 
study was the single one of the abovementioned three including also a QoL 
measurement, showing significant deterioration of several aspects of QoL in 
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breast cancer patients in the one-stop group compared to two-stop, and a 
significant increase in patients having benign results. After two months, dif-
ferences between both groups had disappeared. This seems comparable to 
the findings by Murray et al. reporting similar changes in role, social and 
financial functioning after diagnosis of lung cancer in patients randomized 
between a central (one day) arm and a conventional arm, however the true 
rapid pathway effect can be debated after a six week interval of the QoL mea-
surements.22 The study by Montazeri et al.29 evaluating pre-diagnostic QoL in 
breast cancer patients added a long term (more than 6 weeks) follow-up, that 
was therefore not included in this analysis.
discussion
Pre-DiagnostiC anxietY anD QualitY of life
A diagnosis of cancer may lead to distress by several causes: The feeling of 
the threat of the disease itself, symptoms, disability, pain, as well as the 
treatment (surgery, radiotherapy, chemotherapy) or treatment-related toxic-
ity.13,14,51 This review shows that distress and QoL surrounding a potential 
cancer diagnosis are not well and abundantly studied. Many cancer patients 
suffering from psychological distress remain unidentified, due to either un-
derestimation by physicians or underreporting by patients.52,53 Pre-diagnos-
tic distress is likely to remain unrecognized as well, but can reach extremely 
high levels, i.e. a 33%-60% prevalence of potential clinical anxiety. In other 
words: Suspected cancer patients have similarly or even more negatively af-
fected anxiety and QoL compared to after a confirmed diagnosis during the 
course of their disease; patients who’s diagnostic analysis renders a benign 
outcome are equally affected. 
Though the possibility of a cancer diagnosis in our opinion can be seen as a 
factor in itself for the development of distress, one may assume that it is in-
fluenced by all the known risk factors predicting psychological morbidity in 
cancer: family or personal history of a psychiatric disorder, low socioeco-
nomic position, lack of support, female gender, younger age, advanced or 
active disease, recent stressors and pain or other poorly controlled symp-
toms.9,51,54 None of these factors could be taken into account in the studies 
reviewed, except for an inevitable sex bias due to overrepresentation of breast 
cancer studies and underrepresentation of studies on other prevalent cancer 
types like lung and gastro-intestinal cancer. 
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Then there is the cancer type as specific risk factor: We found pre-diagnostic 
distress levels to be very different compared to levels reported during the 
course of disease.2 Suspected melanoma and lung cancer patients had lower 
anxiety levels in two studies.27,37 The lower levels in melanoma patients could 
be explained by the relatively lower actual melanoma incidence found and 
by the generally definite effect of the diagnostic procedure being therapeutic 
at the same time. The relatively lower level in the study on lung cancer pa-
tients could be explained by the patient sample, consisting of only 40% fe-
males and the selective use of data leaving out all patients eventually not 
diagnosed with lung cancer for whom pre-diagnostic anxiety levels were sig-
nificantly higher. Furthermore there’s a possibility of awareness of the can-
cer diagnosis among 30% of the study sample since the authors state this in 
another article reporting on QoL of the same study sample.47 Certainly for 
lung cancer, known to harbor the highest distress prevalence of all cancer 
types during the disease course, one would assume both higher anxiety 
scores and more studies on patients confronted with a possible lung cancer 
diagnosis. 
The high anxiety scores in suspected ovarian cancer patients were possibly 
influenced by both pre-surgery distress, and the fact that other diagnostic 
procedures could have been done before first anxiety assessment.41
The results of this review with respect to pre-diagnostic levels of anxiety 
should be interpreted with caution. Distress as assessed in some studies 
focuses on a specific diagnostic procedure, rather than a diagnostic work-up 
as a whole. This could either lead to overestimation of distress when patients 
are interviewed shortly before the procedure or underestimation assuming 
multiple diagnostic procedures cause more distress than the single one. The 
true effect remains unclear. 
the effeCt of raPiD DiagnostiC PathwaYs on short term  
Distress anD QualitY of life 
When evaluating the effect on short-term distress and the effect of a rapid 
one-stop or two-stop diagnosis, this review not only shows both statistically 
and clinically significant decreases of anxiety in case of benign disease ir-
respective of cancer type, but also that this concerns a large patient group. 
In case of confirmation of suspected cancer anxiety tends to increase or sus-
tains. The single study evaluating depression in a one stop setting revealed 
more depression after a rapid cancer diagnosis though still on a subclinical 
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level with an in our opinion clinically irrelevant change. In all, this implies 
a beneficial effect of a rapid diagnostic pathway on distress in case of benign 
disease. This was confirmed by studies specifically aiming at rapid pathways, 
and also by two other studies that though not truly rapid pathway studies, 
can be interpreted as such: anxiety levels of patients presenting with a sus-
pected skin lesion at a pigmented lesion clinic that was clinically diagnosed 
as benign decreased significantly but sustained when biopsy was needed;37 
the same effect was found in the breast cancer study by Lampic for patients 
having an immediate benign outcome.37 This effect might be associated with 
the superior patient satisfaction in rapid diagnostic pathways.20 The fact that 
no long-term sequelae of a rapid benign diagnosis were found in the studies 
reviewed, suggests absence of a long-term detrimental effect of the speedier 
benign diagnosis on anxiety. For patients that eventually receive a cancer 
diagnosis, anxiety levels show sustainment or increase (though the clinical 
relevance of this increase in several studies can be debated) suggesting at 
least non-inferiority of rapid compared to non-rapid diagnostic pathways. 
However most was reported in breast cancer patients, derived from relative-
ly small studies and therefore careful interpretation of results is mandatory. 
In general, QoL has a tendency to decrease after a cancer diagnosis, but de-
creased faster when the diagnosis was faster and reacted oppositely in case 
of benign disease, though in a single one stop study with hardly relevant 
changes in clinical point of view.36 Of all cancer types of the studies reviewed, 
lung cancer has by far the worst prognosis. One might expect this to have an 
impact on QoL, but comparison based on the studies found is impossible: 
The study by Lheureux et al.49 reported some decreases in several QoL scales 
after a mean diagnostic period of over three weeks; a bias however was that 
all patients had been hospitalized. In the single study on suspected lung 
cancer patients in a rapid outpatient pathway, follow-up levels of QoL were 
possibly influenced by the fact that far more patients in the rapid arm had 
already started therapy in the rather long six week interval of QoL measure-
ment; actual QoL levels were not reported so no statement can be made on 
whether these changes also were clinically relevant.22
conclusion
Patients confronted with a possible cancer diagnosis report very high dis-
tress levels and decreased QoL. The reduction of distress after exclusion of 
cancer implies a beneficial effect of a rapid diagnostic pathway for those with 
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a benign diagnosis. For those who eventually appear to have cancer, the rap-
id pathway shortens the period of diagnosis related distress and the rela-
tively few studies we found on this specific subject suggest absence of a det-
rimental effect on anxiety compared to regular pathways. More research is 
needed to shed a light on the process suspected cancer patients go through, 
and special attention should be paid to cancer types with high prevalence 
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ABstrAct
oBjeCtIve: Timeliness may influence emotional distress during the diag-
nostic phase of suspected lung cancer patients. We performed a prospective 
observational study to compare distress and quality of life (QoL) in two med-
ical centres with a Rapid Outpatient Diagnostic Program (RODP) and two 
using conventional Stepwise Diagnostic Approach (SDA) based on trained 
nurse led care.
Methods: Outpatients with radiological suspicion of lung cancer completed 
the Hospital Anxiety and Depression Scale (HADS), European Organization 
for Research and Treatment of Cancer 30-item Quality of Life Questionnaire 
(QLQ-C30) and its 13-item Lung Cancer specific module (QLQ-LC13) upon 
first visit, two days later, thereafter weekly for five weeks and after three 
months. 
results: The 72 SDA patients and 121 RODP patients had a mean pre-diag-
nostic HADS-total score of 13.5 (SD 7.6); 63.4% had a score ≥10. Baseline QLQ-
C30 global QoL was 61.6 (SD 22.7) exceeding reference values for lung cancer 
patients. Generalized least square models showed a significant centre by 
time interaction effect: During the first 6 weeks HADS-total scores decreased 
in RODP patients (13.8 to 11.9) but sustained in SDA patients (13.1 to 13.6) 
while QoL showed no relevant changes. Times to diagnosis and discussion 
of therapy plan for RODP patients were 7 and 11 days shorter, respectively. 
ConClusIons: Suspected lung cancer patients had high baseline distress 
levels. A decrease over time was found in RODP compared to SDA patients. 
QoL did not change relevantly. Albeit observational, these data indicate that 
patients experience less distress in rapid diagnostic programs than in step-
wise diagnostic evaluation.
BAckground
Many cancer patients experience emotional distress. The National Compre-
hensive Cancer Network definition of distress is a multifactorial unpleasant 
emotional experience of psychological, social and/or spiritual nature that 
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may interfere with the ability to cope with cancer.1 Distress is mostly charac-
terized by anxiety or depressive symptoms and with prevalences ranging 
form 20-50%2,3 these play an important role in cancer. Deservedly, distress 
has become a well-acknowledged issue in oncological supportive care1 and 
should be considered equally significant at the moment of confrontation 
with the diagnosis. 4 Although studies are neither abundant nor uniform and 
mostly limited to breast cancer patients, they at least suggest very high dis-
tress levels (specifically anxiety) in patients confronted with the mere pos-
sibility of a cancer diagnosis, sustaining after confirmation of the diagnosis 
but reducing after exclusion of cancer.5 The psychological impact of the diag-
nostic phase is additionally highlighted by studies on outcomes of breast 
cancer screening showing that patients eventually not diagnosed to have 
cancer still may experience psychological consequences afterwards.6 Lung 
cancer patients report general distress levels during the course of disease 
that are among the highest of all cancer types.2,3 In this respect they may be 
considered a different patient group which is more at risk, also around diag-
nosis; a substantial group as well if the recent calls for implementation of 
lung cancer screening7 are adopted. Being diagnosed with cancer takes time, 
which can be minimized by a one-stop or two-stop pathway (for which we use 
the generalized term ‘Rapid Outpatient Diagnostic Program’ (RODP)). RODPs 
have been developed for several cancer types.8 Especially in lung cancer, of-
ten requiring multiple diagnostic and staging procedures, an RODP is a valu-
able tool to improve timeliness.9,10 An RODP shortens the diagnostic period 
and in turn the period of diagnosis-related distress, without detrimental ef-
fects on anxiety compared with conventional pathways as was demonstrated 
in breast cancer patients.11-13 However suspected lung cancer requires a dif-
ferent usually more invasive diagnostic approach and patients might, as 
stated before, be more at risk. The present article addresses the question 
whether timeliness of the diagnostic evaluation has an effect on distress and 
quality of life (QoL) in patients with suspected lung cancer. We report the 
results of the PENELOPE study (Pulmonary Evaluation of NEoplastic Lesions 
in Outpatients and it’s Psychological Effects) that was designed to evaluate 
patients in a prospective observational design using validated distress and 
QoL measures before and during the diagnosis of a possible lung cancer up 
to three months in four different medical centres in The Netherlands com-
paring RODP with regular standard diagnostic approach (SDA). We hypoth-
esized that patients in an RODP would experience less distress and a better 
QoL during the diagnostic phase than during conventional SDA; further-
more we hypothesized equal distress and QoL scores at baseline before diag-
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nostic analysis for both patient groups and higher scores than general refer-
ence values for lung cancer patients. Although studies on emotional distress 
usually focus on anxiety, we chose distress as primary endpoint; a broader 
term and a parameter that is more comparable after the 3 months interval 
when the acute anxiety symptoms usually play a less important role and 
depression may be the factor promoting distress.
Methods
PartiCiPants anD ProCeDures
Between January 2009 and July 2010 we performed the PENELOPE study for 
suspected lung cancer patients in two university medical centers (Radboud 
University Nijmegen Medical Centre (RUNMC) and University Medical Cen-
tre Groningen (UMCG)) and two general hospitals (Gelderse Vallei Medical 
Centre (GVMC) and Atrium Medical Centre Heerlen (AMCH)) in the Nether-
lands. In both subsets one center with an RODP and one using an SDA were 
selected. In the RUNMC RODP patients underwent laboratory investigation, 
integrated 18F-fluorodeoxyglucose Positron Emission Tomography-Comput-
ed Tomography (FDG-PET/CT) scan, pulmonary function test, consultation 
with pulmonary physician, and bronchoscopy in two days time and received 
cytology results on the second day, Endoscopic Ultrasound (EUS) or Endo-
bronchial Ultrasound (EBUS) and further pathology results later that week or 
ultimately the seventh day if applicable. The AMCH implemented an RODP 
based on a three day schedule: FDG-PET/CT, pulmonary function tests and 
laboratory investigation on the first, bronchoscopy on the second and/or EUS 
of EBUS on the third and pathology results on the seventh day. Both other 
centres used an SDA based on trained nurse-led care. For this study all pa-
tients with a radiological suspicion of lung cancer were eligible if they were 
over 18 years old and were able to complete printed questionnaires. Patients 
were given verbal and written information about the study. After obtaining 
informed consent, patients were asked to complete sets of questionnaires on 
that day (day one) and day three, and thereafter weekly for five weeks. A final 
questionnaire was sent by mail three months after the last to enable com-
parison of both groups’ scores after the diagnostic process itself. Patients’ 
baseline demographic and disease characteristics and final diagnosis were 
recorded and collected after the study was completed. 
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Questionnaires
Questionnaires were completed at home and returned by mail. Sets consist-
ed of the Hospital Anxiety and Depression Scale (HADS),14 the European Or-
ganization for Research and Treatment of Cancer (EORTC) 30 item Quality 
of Life Questionnaire (QLQ-C30)15 and its 13 item Lung Cancer specific mod-
ule (QLQ-LC13)16 and the EuroQol-5D questionnaire.17 We present results of 
the first two questionnaires in this article because we were specifically inter-
ested in distress and QoL. Not relevant for this study was the EuroQol-5D 
questionnaire, measuring health states specifically for the valuation of 
health in health economy studies. The HADS is a 14-item questionnaire con-
sisting of two subscales: anxiety and depression. Items are rated on a 4-point 
scale, rendering a maximum total score of 21. On either subscale, scores of 
0–7 are considered normal; scores of over 11 are considered a significant 
‘case’ of psychological morbidity, scores of 8–10 are considered ‘borderline’ 
and indicate potential clinical anxiety or depression. A large meta-analysis 
concluded that a total score of 10 or more is the optimal threshold for sig-
nificant emotional distress.18 The major advantage of the HADS is exclusion 
of physical symptoms of anxiety and depression such as weight loss and fa-
tigue. It has been well validated against structured clinical interviews (the 
‘gold standard’ for the assessment of mental disorders) and is considered a 
reliable, sensitive and specific screening tool for psychological distress in 
oncology.19 The EORTC QLQ-C30 is a frequently used cancer specific QoL 
questionnaire, widely accepted for its validity20 containing 30 items on pa-
tients’ functioning, global QoL and both disease and treatment related 
symptoms. Raw scores are linearly transformed to give standard scores in 
the range of 0-100 for each of the functioning and symptom scales. Higher 
scores in the global and functioning scales and lower scores in the symptom 
scales indicate better QoL. A difference of 5-10 points in the scores represents 
a small change, 10-20 points a moderate change and greater than 20 points 
a large clinically significant QoL change.21
outComes
The outcomes of the study were distress (reflected by the HADS-total score), 
anxiety (HADS-anxiety subscale), depression (HADS-depression subscale) and 
QoL (QLQ-C30 global QoL) at baseline (day one) and during the entire diag-
nostic analysis (day one to week six). 
P.Brocken_170x240mm_bw_v13.indd   70 05-01-15   14:32
71
statistiCal Power 
We calculated that, based upon a single measurement per sampling unit, for 
a power of 0.8 with a=0.05, 63 patients were needed in both RODP and SDA 
groups to show a significant 10-20 points ‘moderate difference’ in global QoL 
score QLQ-C30.21
Data analYsis 
We used generalized least squares models to model the course of distress 
and QoL over the first 38 days, which enabled us to explore the dependency 
caused by the repeated measurements on the same patients. A Toeplitz cor-
relation structure coupled with heterogeneous variances provided the best 
fit for these data, based on the Aikike information criterion. The dependent 
variables were distress levels (reflected by the HADS total score), HADS anx-
iety subscore levels and the QLQ-C30 global QoL score. Dependent variables 
were time (entered into the model as a factor with 7 levels), centre type (RODP 
and SDA) and the interaction between these two. A significant interaction 
implies that the course over time is different for the two centre types. Figures 
depicting the estimated marginal means (with standard errors) based on 
this model are presented. Analyses were repeated within strata defined by 
gender and diagnosis outcome (benign and malignant). The measurement 
at three months was analysed separately since the much larger time would 
necessitate a much more complex correlation structure; moreover, centre 
type was not expected to still have an effect on outcomes given the long in-
terval since diagnosis. An advantage of generalized least square models is 
that subjects with a missing outcome on a certain time point can contribute 
to the results using the observations that are present, assuming that the few 
missing values did not influence outcome. All data were analyzed using the 
SPSS 19 statistical software program (SPSS, Chicago, IL). Continuous vari-
ables were compared using the unpaired t-test or Mann–Whitney-U test; cat-
egorical variables were compared using the χ2-test. Differences were consid-
ered statistically significant if p < 0.05.
results
Patients
Figure 1 shows a flow chart of the 407 patients that had been asked to par-
ticipate between January 2009 and July 2010; eventually 193 patients returned 
one or more questionnaires. Three RODP patients and one SDA patient died 
before completing the last questionnaire at 3 months. Patient numbers per 
































407 patients asked to participate






























SDA in RODP center: 1
refused further analysis: 1
clinical instead of outpatient analysis: 3
RODP rescheduling due to PET malfunction: 2
visual impairment: 1 
died before inclusion: 1
FIGURe 1    flow chart 
of patient inclusion, 
reasons for exclusion, 
numbers of returned 
questionnaires at  
different time points 
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participating centre were as follows: RUNMC 87 (45.1%), AMCH 34 (17.6%), 
GVMC 55 (28.5%) and UMCG 17 (8.8%). 
As shown in table 1, this resulted in significantly more tertiary care patients 
and more patients with synchronous or recent cancer diagnoses in the RODP 
group compared to the SDA group, however no significant differences in age, 
gender, lung cancer diagnosis and curative therapy were found. Separate 
analysis of the 104 lung cancer patients showed that significantly more pa-
tients in the RODP were surgically treated. Furthermore, as might be ex-
pected as a result of the different practice organizations, median times to 
reach a diagnosis and discuss therapy plan were 7 and 11 days shorter for 
RODP patients, respectively. However, the interval between first visit and ac-
tual start of therapy in case of lung cancer was not significantly different.
Pre-DiagnostiC Distress anD Qol
Pre-diagnostic distress as measured by the baseline mean HADS total score 
was 13.5 (SD 7.6), or from a different perspective, 63.4% of patients had a 
HADS-total score of 10 or higher, indicating significant distress. Further-
more, 51.8% of patients had a HADS-anxiety score over 7 (borderline anxiety) 
and 19.8% scored over 10 (case anxiety). Baseline mean HADS-total scores of 
patients with a cancer diagnosis were higher (14.7) when compared to pa-
tients with a benign outcome (11.8, p 0.010) as were mean HADS-anxiety 
scores (8.3 and 6.7 respectively, p 0.009); for HADS-depression scores there 
was a trend towards lower scores in SDA patients (6.4 and 5.2 respectively, p 
0.052). Comparison of baseline EORTC QLQ-C30 and LC-13 subscales be-
tween patients with eventual malignant and benign results revealed signifi-
cant and relevant (more than 10 points) differences only in physical function-
ing (74 and 84 respectively, p 0.002) and appetite loss (26 and 15 respectively, 
p 0.002). Mean HADS total scores at baseline were not statistically different 
between men and women (13.0 and 14.5 respectively, p 0.20), neither were 
HADS depression scores (p 0.71) although baseline mean HADS anxiety score 
tended to be higher in women (8.4) compared to men (7.2, p 0.502). Baseline 
HADS-total scores did not differ significantly between RODP and SDA pa-
tients, but HADS-anxiety scores did (8.2 and 6.5, respectively, p 0.01, table 
1).Pre-diagnostic global QoL for all patients was 61.6 (SD 22.7) measured by 
the global QoL score of the QLQ-C30 and was not statistically different be-
tween RODP and SDA patients. Subscores were not significantly different 
between centres types, only fatigue was reported significantly more often in 
the SDA group (table 1).
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 table 1    patient baseline clinical characteristics
N	(%),	or	median	(IQR).
>>> continue on next page
clinical characteristics rodP centres sda centres P
  n= 121 n=72
Mean age (SD) 63.4 (9.6) 64.9 (8.9) 0.26
Tertiary Care centre 87 (71.9)  17(23.6) < 0.001
Male 75 (62) 48 (66.7)
Female 46 (38) 24 (33.3) 0.43
Cancer history:
 any history of cancer 34 (28.1) 9 (12.5) 0.01
 over 5 years ago 18 (14.9) 6 (8.3) 0.18
 1-5 years ago 15 (12.4) 3 (4.2) 0.06
 less than 1 year and synchronous 16 (13.2) 1 (1.4) 0.01
Median time intervals in days:
 visit to diagnosis 7 (0-17) 14 (12-26) < 0.001
 visit to lung cancer therapy plan 8 (1-21) 19 (14-27) < 0.001
 visit to lung cancer therapy 31 (19-43) 37 (26-48) 0.08
Diagnosis lung cancer 62 (51.2) 42 (58.3)
Other diagnosis: 59 (48.8) 30 (41.7) 0.34
 non-malignant 49 (40.5) 24 (33.3)
 metastasis 8 (6.6) 1 (1.4)
 no diagnosis, follow up 2 (1.7) 5 (6.9) 0.03
Lung cancer clinical Stage (N=104):  
 stage I-IIIA 37 (59.7) 18 (42.9)
 stage IIIB-IV 25 (40.3) 24 (57.1) 0.09
Lung Cancer Therapy  (N=104):
 surgical 29 (46.8) 8 (19.0)
 non-surgical 29 (46.8) 26 (61.9)
 none 4 (6.5) 8 (19.0) 0.01
Lung Cancer Therapy (N=104):
 curative 40 (64.5) 24 (57.1)
 palliative 18 (29.0) 10 (23.8)
 none 4  (6.5) 8 (19.0) 0.14
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clinical characteristics:  rodP centres sda centres P
MEAN BASELINE QUESTIONNAIRE SCORES n= 121 n=72
 HADS total score 13.8 (7.6) 13.1 (7.8) 0.55
 HADS anxiety subscale 8.2 (4.2) 6.5 (4.0) 0.01
 HADS depression subscale 5.5 (4.2) 6.5 (4.5) 0.11
Qlobal QoL
 QLQ-C30 63.6 (23.2) 58.2 (23.3) 0.11
QLQ-C30 functioning scores
 physical 78.5 (20.7) 78.4 (19.7) 0.99
 cognitive 82.8 (17.5) 83.8 (19.9) 0.71
 emotional  67.4 (21.9) 69.6 (22.8) 0.50
 role 72.7 (29.2) 70.2 (29.9) 0.57
 social 87.2 (20.4) 84.3 (19.1) 0.32
QLQ-C30 symptom scores
 financial difficulties 8.1 (19.8) 6.6 (17.5) 0.60
 dyspnea 35.8 (31.4) 38.0 (32.0) 0.64
 pain 17.2 (25.5) 24.4 (27.7) 0.07
 fatigue 29.1 (24.8) 38.7 (27.1) 0.01
 sleep 31.1 (33.3) 32.4 (31.9) 0.80
 appetite loss 21.9 (31.0) 21.6 (29.9) 0.94 
 nausea 5.1 (11.4) 7.7 (17.8) 0.22 
 constipation 8.6 (19.6) 7.5 (18.0) 0.70 
 diarrhea 8.6 (18.6) 4.2 (13.7) 0.09
table 1 seqUal    
Baseline	mean	(SD)	anxiety,	depression,	and	QoL	scores.HADS:	Hospital	Anxiety	and	Depression	Scale,	
QLQ-C30	European	Organization	for	Research	and	Treatment	of	Cancer	30	item	QoL	Questionnaire. 
the Course of Distress anD Qol
Distress levels measured with the total HADS scores during the course of the 
diagnostic evaluation of all patients are depicted in figure 2. Over time, 
HADS-total scores decreased in RODP patients from 13.8 at baseline to 11.9 
on day 38 but sustained in SDA patients (13.1 and 13.6 respectively), showing 
a significant centre (2) by time (7) interaction effect (p = 0.034). The HADS-
anxiety subscale showed a similar interaction effect (p = 0.029) over time. A 
small but statistically significant between-groups effect (p = 0.038) became 
apparent for HADS-D scores being slightly higher in SDA patients (differ-
ences between 0.4 and 2.0), however there was no interaction effect. After 
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76 three months, the differences in HADS-total scores between RODP and SDA 
patients disappeared (mean 11.5 and 11.8, respectively, p 0.91). Patients with 








































FIGURe 2    hads-total scores of all sda and rodp patients over time, means and 
standard errors of means 
 roDP sDa
Day 1 13.8 (0.7) 13.1 (0.9)
Day 3 13.9 (0.8) 13.2 (1.0)
Day 10 12.7 (0.8) 14.0 (1.0)
Day 17 11.9 (0.8) 13.5 (1.0)
Day 24 12.1 (0.8) 14.1 (1.0)
Day 31 11.7 (0.9) 13.7 (1.1)
Day 38 11.9 (0.9) 13.6 (1.2)











































FIGURe 3    hads-total scores in patients with benign and malignant diagnoses, 
means and standard errors of means
 sDa roPD sDa roPD
 malignant malignant malignant malignant
Day 1 15.0 (1.1) 14.5 (0.9) 10.2 (1.6) 12.3 (1.1)
Day 3 15.0 (1.2) 15.0 (1.0) 10.4 (1.6) 11.6 (1.1)
Day 10 16.0 (1.2) 13.0 (1.0) 11.0 (1.7) 11.6 (1.2)
Day 17 16.2 (1.3) 12.6 (1.1) 9.2 (1.6) 10.3 (1.2)
Day 24 17.2 (1.3) 13.6 (1.1) 9.4 (1.6) 9.5 (1.2)
Day 31 16.6 (1.3) 13.0 (1.1) 8.9 (1.8) 9.7 (1.4)
Day 38 17.6 (1.5) 13.6 (1.2) 7.4 (1.7) 9.2 (1.3)
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Reviewing both genders separately, a centre type (2) by time (7) interaction 
effect (p 0.043) on HADS-total scores was found in men (p 0.043) but not in 
women (p 0.49). As for diagnosis, patients with a cancer diagnosis (lung and 
other) reacted significantly differently in RODP compared to SDA centres in 
terms of HADS total scores (figure 3, p 0.010) but patients with benign dis-
ease did not (p 0.78). In these patients, similar differences were found for 
both HADS-anxiety subscale (p 0.027 and 0.761, respectively), and HADS-
depression subscale (p 0.005 and 0.603, respectively).
The mean QoL as indicated by the QLQ-C30 global scale showed neither sig-
nificant differences between RODP and SDA patient groups (p 0.131) nor 
clinical relevant changes (i.e. less than 5 on the 0-100 scale21) over the 6 weeks 
that patients were followed. No differences were observed between both gen-
ders (p 0.214 for women, 0.56 for men). However in patients with benign di-
agnoses QoL improved 10.9 (moderate change) for SDA and 7.51 (light change) 
for RODP patients (p 0.40); patients with cancer did not show relevant chang-
es during the course of the study. Since cancer history and surgery were more 
prevalent in RODP patients, we tried to determine whether these resulted in 
different patterns of HADS-total, HADS-anxiety and QLQ-C30 global scale 
but found no significant interaction effect.
discussion
This observational study shows that in patients in the diagnostic phase of 
suspected lung cancer, pre-diagnostic distress levels are very high, not only 
at baseline but also during the first weeks of diagnostic evaluation when al-
most two thirds of suspected lung cancer patients reach substantial distress 
levels.14,18 Distress levels show different patterns over time: sustainment of 
distress in SDA patients and distress decrease in RODP patients. These find-
ings are important since distress during the diagnostic phase of lung cancer 
has not been studied before5 and many cancer patients suffering from psy-
chological distress often remain unidentified.22,23
Pre-DiagnostiC Distress
Pre-diagnostic distress of suspected lung cancer has only been reported by 
Montazeri et al:24 16% of patients had HADS-anxiety scores over 7, and 10% 
over 10 - remarkably low compared to our findings (51.8% and 19.8% respec-
tively), especially when taking into account the possible bias of this study in 
reporting results of patients with a confirmed lung cancer diagnosis only. In 
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fact, our results are much more in line with studies on suspected breast can-
cer patients reporting baseline HADS-anxiety levels over 8 in 46-63%12, 13,24,25 
and over 10 in 28-48%11,12,26 of cases. Although other studies on pre-diagnostic 
anxiety used different instruments, high levels were reported in suspected 
breast, ovarian and prostate carcinoma patients.9 This may confirm that the 
suspected lung cancer patient is not different from other suspected cancer 
patients in terms of distress levels, and moreover that the extreme levels in 
the present study are not unusual.
A remarkable outcome was that patients with an eventual cancer diagnosis 
in our study had significantly higher baseline distress levels compared to 
those with benign disease. Two studies in breast cancer patients27,28 reported 
similar findings, possibly reflecting (non-verbal) cues that patients might 
have perceived from their physician.28 We cannot exclude that patients may 
have experienced more distress due to symptoms and therefore suspecting 
a worse outcome, as analysis of subscores of the QLQ-C30 and QLQ-LC13 
questionnaires showed small but possibly relevant differences in patients 
with an eventual cancer diagnosis experiencing less physical functioning 
and more appetite loss. Furthermore, information given by the general prac-
titioner at referral may have played a role and finally, since lung cancer is 
usually still smoking related, feelings of guilt due to previous smoking.
Distress: the effeCt of timeliness
Regarding our hypothesis on the effect of an RODP in terms of distress, we 
found that over time distress reflected by HADS-Total and HADS-Anxiety 
scales decreasing faster in RODP patients. This may suggest a beneficial ef-
fect of the shorter time interval to reach a diagnosis and/or the programmed 
approach itself on patients’ mental well-being. Post hoc analysis showed that 
this benefit was more profound in males and patients with an eventual can-
cer diagnosis. Eventually after three months, differences disappeared and 
distress levels decreased, although cancer patients were still far above the 
10-point threshold indicating persisting distress.18 Other studies in this re-
spect are limited, small and focus on suspected breast cancer patients:9 Dey 
et al.13 found a significantly larger reduction of anxiety in one-stop evaluation 
compared with two-stop evaluation (in which suspected breast cancer pa-
tients were still awaiting results). This difference disappeared after three 
weeks. In two other studies,11,12 suspected breast cancer patients who were 
given benign results rapidly experienced significantly less anxiety after one 
week than those still waiting for results. After communication of malignant 
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results, all studies showed equal increases of anxiety levels irrespective of 
diagnosis or diagnostic pathway.
Qol
Baseline global QoL was around six points higher than the reference lung 
cancer patients’ values after diagnosis29 and did not change relevantly de-
spite the high distress levels and different diagnostic organisation types. 
This contrasts with the QoL results in the study by Harcourt et al.11 in sus-
pected breast cancer patients showing significant deterioration of several 
aspects of QoL in a one-stop diagnostic group compared with two-stop, and 
a significant increase in patients having benign results. Murray et al. report-
ed similar decreases in role, social and financial functioning after diagnosis 
of lung cancer in patients randomized between one-day and conventional 
evaluation, however this comparison was performed after six weeks.30
CliniCal imPliCations, limitations anD strengths
Despite the descriptive and retrospective nature of the study, it has a wide 
socioeconomic and geographical range reflecting the population of lung 
cancer patients in present day practice in the Netherlands. The results should 
at least raise awareness among clinicians about the very high distress levels 
in suspected lung cancer patients; implementation of an RODP can be a rel-
atively simple tool to address these.
This study features a substantial patient sample, followed over a longer pe-
riod at fixed intervals during the diagnostic episode. To our knowledge, this 
has not been performed before. Although observational in design, it was 
performed as a multicentre study with university and general hospitals in 
both subsets of compared patients groups and relatively few missing data.
This study has some limitations. It is not a randomised trial, and although 
randomisation of this patient category is virtually impossible, should be in-
terpreted with care. First, generalizability is restricted: more patients were 
included in ROPD centres compared to SDA centres, the largest contributing 
centre being a university hospital, although post-hoc analysis showed no in-
teraction effect of surgery or cancer history (more frequent in the RODP pa-
tient sample) on the outcome parameters. Since PENELOPE is a descriptive 
study, we could not control for differences in atmosphere or in approach by 
medical personnel possibly influencing outcome variables, although the ef-
fect of the latter factor is probably limited as patients were seen by different 
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medical personnel per centre. Furthermore, smoking status was not record-
ed, and given the known associations between smoking and lung cancer, 
this may have been an important variable. Second, missing patient reported 
data required remodelling the course of distress and QoL by generalized 
least squares model. Third, post-hoc analysis showed that the interaction 
effect regarding HADS-total scores over time was different between genders, 
with male patients reporting highest scores; a remarkable finding since in 
various cancer types usually women (especially younger women) report high-
er scores than men. Therapeutic factors might have contributed to this dif-
ference, such surgery (which was less performed in SDA patients) or the in-
tensity of the specific treatment.31 Finally, half of all eligible patients refused 
participation. Questionnaire participation rates are rarely specifically stud-
ied, but the low rates in our patient category may not be unusual: Participa-
tion rates of 39-42% have previously been reported in smoking-related cancer 
studies32,33 and were possibly related to smoking. Additionally, the substan-
tial number of questionnaires in our study may have discouraged patients to 
participate.
conclusion
Our study is the first to compare diagnostic pathways in terms of perceived 
distress in suspected lung cancer patients, and demonstrates high distress 
levels at baseline before diagnosis, remaining elevated during diagnostic 
analysis. Within the limitations of its descriptive nature the data suggest 
patients in an RODP approach experienced less distress. After 3 months, dis-
tress level differences between RODP and SDA patients disappeared. Despite 
the distress, QoL was relatively unaffected and increased in patients eventu-
ally not diagnosed with cancer. Clinicians should be aware of the very high 
distress levels in suspected lung cancer patients and may consider imple-
mentation of an RODP to address these.
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suMMAry
Globally, lung cancer is the most prevalent cancer, the first cause of cancer 
death in men and second in women.1 Since lung cancer is specifically smok-
ing related, the lung cancer incidence rate showed a slow but steady decline 
in men in developed countries as a result of decreased tobacco consumption 
during the last quarter of the last century. In women, the incidence rose in 
the western world until recent stabilization.2 However, in the Netherlands 
lung cancer incidence rates appear of epidemic proportions, with a nearly 
30% increase in new lung cancer patients in 2011 compared to 2001 (11669 
and 9009 cases respectively).3 This quite alarming surge is mostly attribut-
able to new cases in females in line with their increased tobacco consump-
tion that commenced in the 1960’s and 1970’s.4 This is illustrated by the fact 
that in 2012, Dutch women aged 45-64 still had a higher former smoking rate 
than women in any other European country.5
The overall five-year survival rate of lung cancer is presently estimated at 
18% for all stages combined6 and hardly improved over the last decades, 
despite the many efforts to find new therapies. With the usual focus on pos-
sible therapeutic improvements for this devastating disease, there has been 
less attention for the diagnostic episode despite the yearly increasing patient 
numbers, especially in the Netherlands. This thesis specifically evaluated 
different aspects of the diagnostic episode of suspected lung cancer, and 
more specifically the role of a rapid systematic approach towards the diagno-
sis of suspected lung cancer by means of a rapid outpatient diagnostic pro-
gram (RODP). From the medical perspective, especially with the increasing 
patient numbers in mind, the value of an RODP in terms of timeliness and 
accuracy of diagnosis and disease stage was estimated. From a patient’s per-
spective, the effects of analysis by RODP on the psychological distress that 
accompanies suspected lung cancer and on quality of life (QoL) were com-
pared with analysis by a regular, stepwise approach.
6
summary and  
general discussion
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timeliness
During the last twenty years, timeliness of the diagnostic process of lung 
cancer has gained attention because of its supposed inverse relation to dis-
ease stage7,8 and survival rates.7-11 Guidelines on lung cancer care have been 
implemented stating specific criteria for referral, diagnostic and treatment 
delay12-15 but research has shown that these were often not met in clinical 
practice.16 In the Radboud University Medical Centre (Radboudumc), an 
RODP for suspected lung cancer patients was implemented in 1999. This 
RODP was based on a two-day schedule and included the specific novelty of 
a routine 18F-fluorodeoxyglucose Positron Emission Tomography-Computed 
Tomography (FDG-PET/CT) scan. In chapter 2 we investigated different as-
pects of diagnostic care in all 565 patients with retrievable medical charts 
out of the total of 570 who had been referred for suspected lung cancer in 
this RODP, during the first 10 years after its implementation. Apart from the 
fact that roughly one third of the patients were referred by a general practi-
tioner (GP) and the other two thirds by a specialist consultant, the patient 
cohort was demographically representative with a mean age of 63.9 years, 
and 66.5% of all patients being male. Calculations based on specified dates 
revealed a median referral, diagnostic and curatively intended therapeutic 
delay of seven, two and eighteen days, respectively. After analyzing all de-
fined delays per stage, diagnostic delay was inversely related to clinical stage, 
contrary to therapeutic delay which was proportionally related. For the sub-
group of patients that had to undergo a diagnostic – and in case of cancer 
also therapeutic – thoracotomy, therapeutic delay, defined by the interval 
between diagnosis and therapy, could be extremely short and therefore 
causes a bias. After exclusion of this subgroup, none of the delays showed a 
relation with clinical or pathological stage. No relation between any delay 
and survival was found.
aCCuraCY of same DaY raPiD CYtologY in ComParison  
to final CYtologY anD PathologY results 
Lung cancer was diagnosed in 51.3% of all patients, of whom 90% had non-
small cell lung cancer (NSCLC), 9.0% small cell lung cancer (SCLC) and 1.0% 
a double tumor consisting of both cell types. Malignant pleural mesothelio-
ma or metastasis of another tumor type was found in 8.3% of patients. A 
certain benign diagnosis (usually infection) was found in 20.4% of patients, 
and in 19.8% no definite pathology diagnosis could be obtained. In 73.2 % 
of these indefinite cases follow-up confirmed a benign outcome; all others 
remained suspected lung cancer cases but further analysis was either deemed 
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futile because of poor performance status or was refused by patients them-
selves. In 59.1% of the 279 lung cancer patients who underwent bronchos-
copy, tissue samples rendered a cytological or histological diagnosis, al-
though this number was lower in the 170 patients without any visible 
endobronchial abnormalities (39.4%). The RODP cytological diagnosis of 
lung cancer was accurate when compared to the bronchoscopy histology re-
sults that were reported in the same week in 97.2% of cases; in four cases 
NSCLC had been mistaken for SCLC, or vice versa.
aCCuraCY of fDg-Pet/Ct within an roDP
Out of all 565 patients, 144 were referred to the RODP with suspicion based 
on an abnormal chest CT-scan that usually had been performed for other 
reasons than a direct suspicion of lung cancer. A chest CT-scan can charac-
terize a lesion much better as probably benign or malignant than a chest 
X-ray. It may indeed be a reasonable option in a stepwise approach towards 
a patient with an abnormal chest X-ray to first perform a CT. However, one of 
the specific characteristics of the RODP is that patients undergo FDG-PET/
CT after a chest X-ray. When assessing the quality of the diagnostic perfor-
mance of such an RODP this is an important patient subgroup and therefore 
in chapter 3, we studied patients that entered the RODP after an abnormal 
chest X-ray separately. This is an important subgroup in usual clinical prac-
tice, as in primary care most lung cancer suspicions start with an abnormal 
chest X-ray. In total 386 patients were analyzed in this cohort; 50.3% were 
referred by a GP. Lung cancer and certain benign diagnoses were eventually 
diagnosed in 61.1% and 20.2% of all cases, respectively. Other cancer types 
such as malignant pleural mesothelioma or pulmonary metastases of a non-
pulmonary tumor were found in 7.0% of cases. The remaining 11.7% of pa-
tients had no pathological confirmation of their lesion(s) but these were con-
sidered benign after not showing growth on CT during follow-up. In 8.3% of 
all patients (8.3%) malignancy might have retrospectively been excluded on 
CT alone as the lesions showed typical benign characteristics, or for instance 
no abnormalities at all. For diagnosis of malignancy, sensitivity was 97.7% 
(95% confidence interval 94.9-99.1%), specificity 60.2% (50.9-68.8%), negative 
predictive value 92.5% (83.8-96.9%) and positive predictive value 84.0% (79.3-
87.8%). Accuracy, defined as the proportion of true results, was 85.8% (81.4-
90.0%). Analysis of delays within this subgroup revealed a median referral 
and diagnostic delay of seven days and one day, respectively. For patients in 
this cohort, ultimately diagnosed with lung cancer, median referral delay 
was also seven days, diagnostic delay two days and therapeutic delay 19 days. 
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Distress of the susPeCteD CanCer Diagnosis anD effeCt  
on QualitY of life
The subsequent two chapters shared patient reported outcomes in the diag-
nostic phase of suspected cancer mainly in terms of distress and Quality of 
Life (QoL). The National Comprehensive Cancer Network defined distress as 
an unpleasant emotional experience of psychological, social or spiritual na-
ture interfering with the ability to effectively cope with cancer. Distress ex-
tends on a continuum ranging from common normal feelings of vulnerabil-
ity, sadness and fears to problems that become disabling, such as depression 
and anxiety.17 Quality of life refers to the functioning of patients on physical, 
psychological and social domains. In an attempt to answer the question on 
how much distress suspected patients encounter during the diagnostic epi-
sode, and what possible effects of an RODP are known, a systematic review 
of the available literature was performed. Chapter 4 described this review 
which resulted in a collection of 23 publications out of a total of 1846 that 
were eligible for review based on publication of prospectively derived data on 
distress, anxiety, depression and QoL in suspected cancer patients before 
and after diagnostic evaluation. Notably, suspected lung cancer was hardly 
represented in these studies; most reported data concerned suspected breast 
cancer patients. Furthermore, the use of different measures for distress and 
QoL complicated comparison between studies. The most frequently used 
measure for anxiety was the Hospital Anxiety and Depression Scale (HADS), 
a 14-item questionnaire consisting of two subscales of anxiety and depres-
sion.18 Items are rated on a 4-point scale, rendering a maximum total score 
of 21. On either subscale, scores of 0–7 are considered normal; scores of 
≥ 11 are considered a significant ‘case’ of psychosocial morbidity, scores of 
8–10 are considered ‘borderline’ and indicate potential clinical anxiety or 
depression. A HADS-total score of 10 or higher is presently regarded as best 
cut-off for screening for severe distress in cancer patients.19 An important 
finding of the review was that pre-diagnostic anxiety as measured by the 
HADS Anxiety subscale (HADS-A), was high in suspected cancer patients (i.e. 
usually suspected breast cancer) showing ‘borderline’ and ‘case’ anxiety lev-
els in 46-73% of patients.20-25 The single study in this review that was per-
formed in suspected lung cancer patients found these levels in 16% of all 
patients.26 The low percentage may have been the result of sampling bias, 
since only data had been used of those patients who were eventually actually 
diagnosed with lung cancer and who were possibly aware of their lung cancer 
diagnosis in this particular study. As for QoL, suspected cancer patients’ pre-
diagnostic general QoL levels were much lower than the random normal 
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reference, with suspected lung cancer patients accounting for the lowest 
scores.25,27-31 
With respect to the effect of a cancer diagnosis on distress, a beneficial effect 
of a rapid benign diagnosis on distress became apparent, in the form of both 
statistically and clinically significant decreases of anxiety in case of benign 
disease, irrespective of suspected cancer type. In case of confirmation of 
suspected cancer anxiety tended to increase or sustain, 22-25,28-37 with the ex-
ception of two studies reporting decreases of anxiety levels after diagnosis 
of melanoma and ovarian cancer patients.38,39 In the end, only three rela-
tively small studies in suspected breast cancer patients were found to report 
data on the effect of a rapid versus a non-rapid diagnosis, and thereby quali-
fied as a comparison between an RODP and regular diagnostic care.22,24,25 
These studies revealed earlier improvements in anxiety scores for patients 
with benign results in rapid pathways, and equal increases of anxiety scores 
in case of malignant results in both rapid and non-rapid pathways. QoL was 
reported in only one of these studies25 on rapid versus non-rapid breast can-
cer diagnosis and showed significant deterioration of several aspects of QoL 
in breast cancer patients in the rapid group, and a significant increase in 
patients having benign results. 
The lack of studies regarding distress and QoL of suspected lung cancer, al-
though known for its high distress levels compared to other malignancies40,41 
was perhaps one of the most striking conclusions of the reviewed literature. 
In order to address this lacuna and to provide answers for this patient group, 
we designed and performed the PENELOPE study (Pulmonary Evaluation of 
NEoplastic Lesions in Outpatients and its Psychological Effects). The study 
was described in detail in Chapter 5. PENELOPE included a large number of 
patients in a prospective cohort design to compare distress and QoL during 
the diagnostic episode of suspected lung cancer in two Dutch medical cen-
ters that had implemented an RODP and two that used a usual Standardized 
Diagnostic Approach (SDA) based on trained nurse led care. We compared 
patient distress and QoL in both diagnostic pathway types, by taking serial 
sets of questionnaires containing several measures. Of these, the results of 
the HADS, the European Organization for Research and Treatment of Can-
cer 30-item Quality of Life Questionnaire (QLQ-C30)42 and its 13-item Lung 
Cancer specific module (QLQ-LC13)43 were reported. The study included 193 
patients who returned one or more questionnaires. Pre-diagnostic distress 
levels turned out to be very high; the baseline mean HADS total score was 
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13.5, or from a different perspective: 63.4% of patients had a HADS-total 
score of 10 or higher,19 indicative of significant distress. Baseline HADS total 
scores were not statistically different between RODP and SDA patients, how-
ever, distress of patients with an eventual cancer diagnosis were higher (14.7) 
when compared to patients with a benign outcome (11.8, p 0.01). Pre-diag-
nostic QoL as measured by the QLQ-C30 global QoL score for all patients was 
61.6 and was not statistically different between RODP and SDA patients. Over 
time, HADS-total scores decreased in RODP patients from 13.8 at baseline to 
11.9 on day 38, but sustained in SDA patients (13.1 and 13.6 respectively), 
showing a significant centre (2) by time (7) interaction effect (p 0.03), which 
was similar for the HADS-anxiety subscale. When separately analyzed, this 
difference between RODP and SDA was seen in male (p 0.04) but not in female 
patients  
(p 0.49), and in patients with a malignant (p 0.01) but not with a benign out-
come (p 0.78). After three months, the differences in HADS-total scores be-
tween RODP and SDA patients had disappeared (mean 11.5 and 11.8, respec-
tively, p 0.91), and patients with a benign diagnosis reported lower scores 
than cancer patients (8.5 and 13.2 respectively, p 0.01)). The mean baseline 
global QoL for all patients was within reference lung cancer patients’ values 
after diagnosis,44 not significantly different between RODP and SDA patients 
and did not change relevantly during the study period.
generAl discussion
Lung cancer care has been affected by major changes during the last de-
cades. As mentioned before, especially in the Netherlands patient numbers 
are rising.3 Accurate staging and tumor characterization are increasingly im-
portant due to the fact that management decisions increasingly depend on 
a combination of tumor stage, tumor type and partly on gene mutation sta-
tus.45,46 The role of the rapid diagnostic pathway may be seen as a pivotal one. 
This thesis shows that an RODP benefits different aspects of diagnostic care. 
Incorporation of an FDG-PET/CT enables the physician to diagnose and 
stage timely within guideline criteria and as confidently as in usual diagnos-
tic care. Moreover, from the patient’s perspective it has added value since the 
reported distress is lower in the first 2 months following RODP compared to 
SDA. 
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the raPiD outPatient DiagnostiC Program for lung CanCer
diagnostic care
As extensively described in chapters 2 and 3, the Radboudumc RODP for 
suspected lung cancer started its programmed approach with FDG-PET/CT 
and included bronchoscopy as the primary diagnostic tool to deliver a tissue 
diagnosis. Whether both diagnostic entities should have this central role can 
be debated, especially regarding bronchoscopy which might not be an obvi-
ous first choice in case of a smaller or more peripherally located tumor and 
nowadays more often Endobronchial Ultrasound (EBUS) is chosen as a first 
diagnostic tool combining both staging and diagnostic properties. That be-
ing said, the utility of bronchoscopy in experienced hands was demonstrated 
by the fact that diagnosis was achieved by bronchoscopy in 59.1 % of all lung 
cancer patients. Furthermore, although in 60.9% of the lung cancer patients 
who underwent bronchoscopy, endobronchial abnormalities to guide direct 
biopsies were lacking, in 39.4% of cytological specimens malignant cells 
were nevertheless detected. Moreover, the malignant same-day cytological 
diagnosis on the bronchoscopy day was in 97.2% of cases confirmed as ac-
curate by the final diagnostic results, reported in the same week. Although 
the smaller sample size of cytology compared to histology therefore not led 
to less accurate results, too small cytology specimens may complicate the 
analysis of gene mutation status. This is often crucial nowadays,46 but not 
common practice during the years of the analyzed RODP cohort. 
The most important (and within the RODP also the first) diagnostic tool was 
FDG-PET/CT, with radiological and nuclear images being conjointly read im-
mediately after the scanning procedure. Chapter 3 demonstrated that even 
for the important patient subgroup that had been referred with abnormal 
chest X-ray, sensitivity, NPV and PPV were within the published range of 
accuracy.47 Although the demonstrated specificity of 60.2% may seem low 
compared to existing data, it is important to emphasize that other studies 
usually included patients with solitary pulmonary nodules on a CT scan, 
inherently increasing the pre-test probability of malignancy. Compared to 
our selection of chest X-ray referred patients, this resulted in a higher speci-
ficity (77.8%).
The obvious downside of an RODP that starts with an FDG-PET/CT is the risk 
of overuse in patients with a final benign diagnosis that appeared malignant 
at referral: Results of more than one third of patients (34.8%) were eventu-
ally definitely or probably (after follow up) benign. Supposedly, this risk may 
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be higher in patients referred with an abnormal chest X-ray, as a chest CT has 
a higher accuracy in the differentiation between benign and malignant lung 
lesions. In retrospect, in 8.3% of all cases of the chest-X-ray based referrals, 
CT without FDG-PET would have been sufficient in ruling out malignancy 
with high certainty. However, interposition of CT between chest X-ray and 
FDG-PET would have had an adverse effect on timeliness.
timeliness
Essential for the value of the RODP was the fact that it resulted in a median 
diagnostic delay of two days (even one day for the subgroup of chest X-ray 
referred patients), which is within any guideline limitation and substantial-
ly shorter than reported delays of 7–37 days in other studies.16 Although this 
was an important observation, also shorter waiting times before and after 
the diagnostic process contribute to the patient experience and the quality 
of cancer care. Analysis of diagnostic and therapeutic delays revealed pos-
sible benefits of the RODP as well. An RODP schedule inevitably increases 
waiting time for part of the referred patients when it is fixed to two weekdays 
(Wednesday and Thursday in case of the Radboudumc RODP). Nevertheless, 
the median waiting time before first visit was seven days and within guide-
line limitations, except for the Dutch Guideline stating a five day maximum. 
12-15 Furthermore, it was shorter than presented in literature with the excep-
tion of only one study.16,48 The delay of 18 days to curative therapy for lung 
cancer patients was in the low range of comparable reports16 and within all 
guideline limitations.12-15 These findings suggest that, despite the fact that 
the RODP was not designed to specifically reduce referral or therapeutic de-
lay, the systematic and multidisciplinary approach to analyze all patients by 
RODP may have had a beneficial effect on both.
Distress anD QualitY of life arounD Diagnosis 
what does penelope learn us?
Both positive and negative effects on lung cancer patients’ wellbeing have 
been attributed to an RODP in the past. Discussions between proponents 
and opponents were supported by contrasting arguments. On the one hand 
the importance of the time the patient should need to get used to the dismal 
diagnosis was stressed, on the other hand the supposed benefit of shorten-
ing the period of uncertainty as much as possible was a main issue.49-51 The 
argumentations were based rather on personal beliefs than science, since at 
the time not many studies existed on distress and QoL before or surrounding 
a potential cancer diagnosis, and as Chapter 4 demonstrated, even less on 
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the influence of an RODP. The PENELOPE study, presented in chapter 5, is 
the first large prospective study demonstrating a beneficial effect of an 
RODP: distress levels in suspected lung cancer patients analyzed in an RODP 
decreased faster over time compared to distress levels in patients analyzed 
in an SDA. This effect on patients’ mental well-being may be explained by 
either the shorter time interval to reach a diagnosis or by the programmed 
approach itself, or by both. Obviously, we should realize that PENELOPE was 
not a randomized but a descriptive study and there were differences between 
including centers in terms of patient characteristics and inclusion numbers, 
which may have had an effect on results. On the other hand, just like the 
patient population described in the Radboudumc RODP, it has a wide socio-
economic and geographical range that reflects the population of lung cancer 
patients in The Netherlands.
distress in suspected cancer
On top of the beneficial result for the suspected cancer patient in an RODP, 
two further findings of the PENELOPE study are of great importance. First, 
the very high distress levels that were found in referred suspected lung can-
cer patients: almost two thirds of patients had distress levels qualifying as 
suggestive of severe distress (HADS-total score of 10 or higher,19 including a 
substantial number of patients that eventually had a benign outcome. In line 
with suspected breast cancer patients22-24,27 these results confirm that the 
suspected lung cancer patient is not quite different in terms of distress levels 
as compared to other suspected cancer patients. This is contradictory to the 
single previous study in suspected lung cancer patients reporting much low-
er distress levels.26 Moreover, this also suggests that these extreme levels 
found before diagnosis are not unusual. A second finding was that mean 
distress scores after three months for both RODP and SDA patients with lung 
cancer were still well above the 10-point distress threshold on the HADS-to-
tal scale, which confirms that lung cancer patients are indeed a group at risk 
for distress. These facts are all the more important since many cancer pa-
tients suffering from psychological distress often remain unidentified due to 
either patient underreporting or underestimation by physicians.53,53 Pre-di-
agnostic distress may remain equally unrecognized as well.
factors influencing distress levels in suspected cancer
With respect to distress after diagnosis, different factors are known to be of 
importance and these have to be taken into account in the comparison and 
interpretation of the literature: Factors such as gender, age, or specific can-
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cer type influence distress.40,54,55 In other words, perhaps the most important 
question is whether the data of suspected breast cancer patients, inherently 
all female and perhaps younger, result in a selection bias when interpreting 
study results. Distress levels in these patients may not be equivalent to those 
in patients with other highly prevalent malignancies such as colorectal or 
lung cancer. Furthermore, different studies use different assessment mea-
sures, and certain studies assess distress around a specific diagnostic proce-
dure, rather than around the diagnostic work-up as a whole. Despite of all 
the above, the studies reviewed in chapter 4 demonstrated a beneficial effect 
of a rapid benign diagnosis on distress in general. In case of confirmation of 
suspected cancer, anxiety tended to increase or sustain, with the exception 
of two studies reporting decreases of anxiety levels after diagnosis of mela-
noma and ovarian cancer patients;38,39 these different outcomes might be at-
tributed to the specific cancer type (in case of melanoma), or the way the 
specific study was performed causing possible bias.38 To equally compare the 
results of PENELOPE, we have to resort to three relatively small studies in 
suspected breast cancer patients analyzed by means of an RODP compared 
to a regular approach, revealing earlier improvements in anxiety scores for 
patients with benign results in rapid pathways, and equal increases in case 
of malignant results in both rapid and non-rapid pathways. In the PENELO-
PE study, it is a remarkable finding that the decrease of distress in an RODP 
appeared more profound in males is remarkable, since the female gender 
has been generally related to higher distress levels.56,57 
The pattern over time of global QoL (EORTC QLQ-C30 global QoL scale) was 
different: in contrast to distress, baseline values positively exceeded the ref-
erence lung cancer patients’ values after diagnosis by around 6 points.58 After 
baseline, QoL did not relevantly change, either over time, or between diag-
nostic organization types despite the high distress levels, and in contrast to 
the deteriorating short term QoL that was found in two other studies on the 
effect of an RODP in breast25 and lung cancer patients.59
the future
An RODP has advantages to the regular stepwise approach, but further im-
provements are imaginable. For instance, in order to reduce patient radia-
tion exposure and to increase cost-effectiveness, the effect of separating the 
diagnostic CT from the FDG-PET on both parameters could be evaluated. As 
mentioned, this may prevent patients from undergoing FDG-PET for benign 
lesions, but may increase the complexity of an RODP system and will pre-
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clude a two-day schedule. Furthermore, the RODP should expand the tech-
niques to obtain a tissue diagnosis by not only including bronchoscopy as 
the primary method but also transthoracic biopsies and/or endoscopic ultra-
sound guided procedures. This could further improve timeliness for those 
patients with peripheral lesions or non-bulky mediastinal metastases. Fi-
nally, another important subject to address is therapeutic delay: from the 
patient’s perspective the interval between referral and start of therapy may 
be equally important.
Apart from the benefits of an RODP on timeliness and accuracy of diagnostic 
care, this thesis shows additional benefits in terms of distress levels. Until 
lung cancer is cured, distress will be following the patient after diagnosis, 
during treatment and beyond, in both curative and palliative settings. And 
since cure is by far not in sight, increased awareness among physicians of the 
risk of severe patient distress from the moment the suspicion of lung cancer 
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sAMenvAtting
Longkanker is wereldwijd de meest voorkomende soort kanker. Daarnaast is 
het de belangrijkste kanker-gerelateerde doodsoorzaak bij mannen en de op 
één na belangrijkste bij vrouwen.1 Longkanker wordt in belangrijke mate 
veroorzaakt door roken. Als gevolg van de verminderde tabaksconsumptie in 
met name de westerse wereld valt er een lichte, maar gestage daling van het 
aantal nieuwe gevallen waar te nemen bij mannen. Bij vrouwen is dit aantal 
gestegen door toename van het aantal vrouwelijke rokers in de laatste decen-
nia van de vorige eeuw. Toch lijkt het aantal globaal gezien te stabiliseren.2 
In Nederland is de incidentie van longkanker echter gestegen van 9009 nieu-
we gevallen in 2001 tot 11669 in 2011, een toename van bijna 30%.3 Deze 
alarmerende toename komt vrijwel geheel voor rekening van de vrouwelijke 
helft van de populatie, in lijn met de toegenomen consumptie van tabak door 
vrouwen in ons land sinds de jaren ’60 en ’70 van de vorige eeuw.4 In 2012 
bleken Nederlandse vrouwen in de leeftijdscategorie van 45-64 jaar frequen-
ter te roken dan hun leeftijdgenoten in andere Europese landen.5
De vijf-jaars-overleving van longkanker, wanneer we alle stadia bijeen ne-
men, ligt momenteel rond de 18%.6 Dit percentage is de laatste decennia 
nauwelijks veranderd, ondanks de vele wetenschappelijke inspanningen om 
betere vormen van behandeling te ontwikkelen. Opvallend is dat onderzoek 
bij longkanker meestal is gericht op therapeutische uitkomsten en niet op 
het diagnostische traject van de patiënt bij wie longkanker wordt vermoed, 
ondanks de zeker in Nederland jaarlijks toenemende aantallen. Juist van dit 
diagnostische traject worden in dit proefschrift diverse aspecten onder de 
loep genomen, en dan met name de invloed van een versnelde en systemati-
sche poliklinische analyse van patiënten bij wie longkanker wordt vermoed: 
de zogeheten sneldiagnostiek. Enerzijds wordt de meerwaarde ervan belicht 
voor het verkrijgen van niet alleen een tijdige, maar ook een correcte diag-
nose, anderzijds wordt de beleving in termen van psychisch welbevinden, 
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tiek en patiënten die de reguliere stapsgewijze poliklinische analyse onder-
gaan.
De tijDsDuur van het DiagnostisChe trajeCt
Het tijdig doorlopen van de diagnostiek voor longkanker heeft de laatste 
twintig jaar meer aandacht gekregen vanwege een verondersteld omgekeerd 
verband tussen het ziektestadium7,8 en overlevingscijfers.7-11 Diverse natio-
nale en internationale richtlijnen zijn geïmplementeerd met specifieke 
maximale ‘doorlooptijden’ voor verwijzing, diagnosestelling en behande-
ling.12-15 Onderzoek heeft echter ook laten zien dat in de dagelijkse praktijk 
deze doorlooptijden vaak veel langer zijn dan richtlijnen voorschrijven.16 In 
het RadboudUMC in Nijmegen werd in 1999 een nieuw instrument voor 
diagnostiek en stadiëring van longkanker geïntroduceerd: de 18F-fluorode-
oxyglucose-Positron-Emissie Tomografie (FDG-PET) gecombineerd met 
Computer Tomografie met röntgencontrast (CT, samen FDG-PET/CT ge-
noemd). Tegelijk hiermee werd een programma voor sneldiagnostiek ont-
wikkeld dat als specifiek novum startte met een FDG-PET/CT voor alle pati-
enten die waren verwezen vanwege een radiologische verdenking van 
longkanker. In de eerste tien jaar na de introductie zijn in totaal 570 patiën-
ten met behulp van dit programma geanalyseerd. 
 In hoofdstuk 2 zijn diverse aspecten beschreven van de 565 patiënten uit 
die periode van wie medische gegevens konden worden achterhaald. Deze 
groep patiënten was representatief voor de reguliere longkankerpatiënt, ge-
zien de gemiddelde leeftijd van 63.9 jaar en de verhouding mannelijk (66.5%) 
en vrouwelijk (33.5%) geslacht. Opvallend was wel het verwijspatroon, daar 
slechts een derde van de patiënten door een huisarts verwezen was, het ove-
rige deel door een medisch specialist. Door van iedere patiënt de doorloop-
tijd te registreren, waren voor de hele groep mediane doorlooptijden te bere-
kenen voor verwijzing (door huisarts of specialist tot eerste bezoek), 
diagnose (eerste bezoek tot diagnose) en curatieve behandeling (diagnose tot 
eerste behandeling); deze kwamen uit op respectievelijk zeven, twee en acht-
tien dagen. Bij vergelijking van hogere en lagere klinische stadia bleek een 
langere diagnostische doorlooptijd gerelateerd aan een hoger stadium; voor 
curatieve behandeling gold het omgekeerde. Van belang bleek ook de sub-
groep patiënten die een diagnostische thoracotomie had ondergaan, een 
zogenaamde ‘proefthoracotomie’ bij verdenking longkanker zonder vooraf 
vaststaande diagnose. In hun geval was de diagnostische doorlooptijd ex-
treem kort en mogelijk verstorend voor de analyse. Na exclusie van deze 
groep bleek er geen verband meer aan te tonen tussen welke doorlooptijd 
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ook met een hoger of lager stadium van ziekte. Er viel evenmin een verband 
vast te stellen tussen doorlooptijd en overleving. 
snelle Diagnose: CYtologie versus Definitieve resultaat 
Bij 51.3% van de patiënten was uiteindelijk sprake van een vorm van longkan-
ker; deze groep bestond voor 90% uit niet-kleincellige longkanker (NSCLC), 
9% uit kleincellige longkanker (SCLC) en in 1% kwamen beide vormen gelijk-
tijdig voor. Metastasen van een andere soort kanker of een maligne mesothe-
lioom kwamen voor in 8.3% van de gevallen. Bij 20.4% van de patiënten werd 
een zekere benigne diagnose gesteld, doorgaans een infectie. Van de gehele 
groep patiënten bleek bij 19.8% geen definitieve diagnose te stellen; bij bijna 
driekwart van hen (73.2%) bevestigde het vervolgen van de radiologische af-
wijkingen het vermoeden van een niet-maligne aandoening. Het overige deel 
hield wel een sterke verdenking op longkanker, maar werd niet verder geana-
lyseerd omdat dit hetzij medisch gezien zinloos werd geacht ten gevolge van 
bijvoorbeeld een sterk verslechterde algehele conditie, hetzij door de patiënt 
werd geweigerd. Van de 279 longkankerpatiënten die een bronchoscopie 
hadden ondergaan, werd bij 59.1% op basis van bronchoscopisch verkregen 
cytologisch of histologisch materiaal de specifieke diagnose verkregen. Dit 
lukte minder vaak als er geen endobronchiale afwijkingen zichtbaar waren, 
namelijk bij 39.4% van de patiënten. De voorlopige cytologische diagnose 
van longkanker was, vergeleken met de definitieve diagnose die dezelfde 
week werd afgegeven, correct in 97.2% van de gevallen; in 4 gevallen bleek 
deze niet correct te zijn en was een NSCLC gehouden voor een SCLC, of an-
dersom.
het DiagnostisCh vermogen van De fDg-Pet/Ct binnen een 
snelDiagnostiek-Programma
Van alle bovengenoemde 565 beschreven patiënten met bekende medische 
gegevens waren er 144 verwezen naar het sneldiagnostiek-programma op 
basis van afwijkingen op een CT-scan, die meestal was gemaakt om andere 
redenen dan een vermoeden van longkanker. Met een CT-scan van de thorax 
valt het vermoeden dat een afwijking benigne of juist maligne is, veel beter 
in te schatten dan op basis van een X-thorax. In een stapsgewijze benadering 
van een patiënt met verdenking longkanker is het heel gebruikelijk om eerst 
een CT te maken. In het sneldiagnostiekprogramma was het juist een bijzon-
der kenmerk dat het mogelijk was dat patiënten met alleen een afwijkende 
X-thorax een FDG-PET/CT ondergingen. Dit is een belangrijke subgroep, om-
dat in de eerstelijns gezondheidszorg de verdenking van longkanker door-
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gaans met een X-thorax begint. Daarnaast is het ook voor het beoordelen van 
de diagnostische waarde van de FDG-PET/CT binnen het sneldiagnostiek-
programma een belangrijke subgroep, die derhalve in hoofdstuk 3 apart is 
beschreven.
Het cohort bestond uit 386 van de 565 patiënten uit de eerdere studie: 50.3% 
van hen was verwezen door een huisarts. Er bleek in 61.1% van de gevallen 
sprake van longkanker, in 20.2% van een benigne afwijking. In 7.0% van de 
gevallen was er sprake van een metastase van een andere tumor of een ma-
ligne mesothelioom. Bij de overige 11.7% van de patiënten is geen diagnose 
verkregen, maar werd de afwijking als benigne beschouwd en vervolgd zon-
der tekenen van groei. Bij 8.3% van dit cohort had retrospectief een CT-scan 
alleen reeds voldoende informatie kunnen geven om een maligniteit uit te 
sluiten, omdat de laesie radiologisch typisch benigne kenmerken vertoonde 
of omdat bijvoorbeeld geen enkele afwijking (meer) zichtbaar was. Ten aan-
zien van de diagnose maligniteit bedroeg de sensitiviteit 97.7% (95%-be-
trouwbaarheidsinterval 94.0-99.1%), specificiteit 60.2% (50.9-68.8%), nega-
tief voorspellende waarde 92.5% (83.8-96.6%) en positief voorspellende 
waarde 84.0% (79.3-87.8%). Het percentage correcte resultaten bedroeg 
85.5% (81.4-90.0%). Voor deze specifieke subgroep is ook de tijdigheid van de 
diagnostiek berekend: de mediane doorlooptijden van verwijzing en diag-
nose bedroegen respectievelijk zeven dagen en één dag, voor de patiënten die 
uiteindelijk longkanker bleken te hebben en behandeld werden respectieve-
lijk zeven en twee dagen, met een mediane doorlooptijd tussen diagnose en 
behandeling van 19 dagen. 
het PsYChisCh effeCt van De verDenking van kanker,  
en het effeCt oP De kwaliteit van leven
De volgende twee hoofdstukken betroffen patiënt-gerapporteerde uitkom-
sten van onderzoek over het diagnostische traject van een verdenking van 
kanker, en dan in het bijzonder psychisch relevante nood, een begrip dat in 
het Engels het best wordt weergegeven door de term ‘distress’ – en daarnaast 
kwaliteit van leven. Volgens de definitie van het National Comprehensive 
Cancer Network is distress een onprettige emotionele ervaring van psycholo-
gisch, sociaal of spiritueel karakter, die het de patiënt verhindert om de ma-
ligne aandoening op een effectieve manier het hoofd te bieden. Het betreft 
hier een continuüm, strekkend van normale gevoelens van kwetsbaarheid, 
verdriet en angsten tot problemen die aantoonbare klachten veroorzaken, 
zoals een angststoornis of depressie.17 Kwaliteit van leven behelst vooral het 
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functioneren van de patiënt op het fysieke, psychische en sociale vlak. In een 
poging om te kwantificeren hoeveel distress patiënten in de diagnostische 
fase van een verdenking op kanker doormaken en het effect van een sneldiag-
nostiekprogramma hierop, is een systematische review van reeds gepubli-
ceerde studies in de wetenschappelijke literatuur verricht. Dit resulteerde in 
hoofdstuk 4 in een bespreking van een verzameling van 23 relevante weten-
schappelijke artikelen uit een totaal van 1846 die in eerste instantie naar 
voren kwamen bij een elektronische zoekopdracht, waarbij in Engelstalige 
literatuur gezocht werd op prospectieve data over distress, angst, depressie 
en kwaliteit van leven bij patiënten met een verdenking van kanker, gemeten 
vóór en na diagnostische onderzoeken. Opvallend genoeg bleken er nauwe-
lijks publicaties te zijn waarin het om een verdenking van longkanker ging; 
het merendeel betrof patiënten met een verdenking van een mammacarci-
noom. Bovendien bleken er bij de verschillende studies ook verschillende 
soorten vragenlijsten te worden gebruikt, hetgeen onderlinge vergelijking en 
kwantificeren lastig maakt. De meest gebruikte vragenlijst was de Hospital 
Anxiety and Depression Scale (HADS), die bestaatuit 14 items, gelijkelijk ver-
deeld over twee schalen: angst (HADS-A) en depressie (HADS-D).18 De items 
scoren op een schaal van 4 punten, waarbij opgeteld een maximale score van 
21 punten mogelijk is. Een score van 0 tot 7 op één van beide schalen wordt 
normaal geacht, scores van 11 of hoger als een significant geval van psycho-
pathologie; scores daartussen worden ‘ borderline’ genoemd en kunnen in-
dicatief zijn voor een potentiële angststoornis of depressie. Vodemaier stelde 
bovendien vast dat wanneer beide schalen opgeteld (HADS-totaal) een score 
van 10 of hoger opleveren, dit waarschijnlijk optimaal de mogelijkheid van 
een psychische stoornis aangeeft.19 
 Een van de opvallende bevindingen van dit review was dat pre-diagnosti-
sche angst, zoals gemeten met de HADS-A vóór het bekend worden van de 
diagnose, erg hoog lag bij patiënten die van kanker (weliswaar dus meestal 
borstkanker) verdacht werden: in 46 tot 73% van de gevallen was er sprake 
van ‘borderline’ of ‘case’ HADS-A scores.20-25 De enige gepubliceerde studie 
over patiënten met een verdenking van longkanker vond deze scores bij 
slechts 16% van de gevallen.26 Hier kan overigens sprake zijn geweest van het 
effect van selectie, omdat alleen patiënten die uiteindelijk daadwerkelijk 
longkanker bleken te hebben in deze studie waren opgenomen en het boven-
dien heel goed mogelijk is dat (een deel van de) patiënten reeds op de hoogte 
was van deze diagnose. Kwaliteit van leven voorafgaand aan de diagnose 
bleek bij patiënten die van kanker verdacht werden veel lager te zijn dan de 
bekende gemiddelde referentiewaarde, waarbij een verdenking op longkan-
ker er nog verder in negatieve zin uitsprong.25,27-31
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Er werd een gunstig (significant en relevant) effect van een benigne diagnose 
gevonden voor angst bij alle onderzochte soorten kanker. Indien het inder-
daad een maligne diagnose betrof, bleven angstscores doorgaans gelijk-
waardig aan die vóór de diagnose, of vertoonden ze een stijging.22-25,28-37 Twee 
opvallende uitzonderingen die juist een daling van de angstscores lieten 
zien, betroffen een studie bij patiënten met een melanoom en een studie bij 
patiënten met een ovariumcarcinoom.38,39
Voor de vergelijking van het effect van een snellere diagnose op bovenge-
noemde aspecten of specifiek van sneldiagnostiek ten opzichte van regulie-
re, stapsgewijze diagnostiek bleken slechts drie studies die aan de zoekcrite-
ria voldeden geschikt. Het betrof in alle drie de gevallen studies bij patiënten 
met een verdenking van borstkanker; de resultaten lieten zien dat angstsco-
res bij een benigne diagnose sneller daalden bij sneldiagnostiek- patiënten, 
en vergelijkbaar stegen bij een maligne diagnose.22,24,25 Kwaliteit van leven 
werd in slechts één van deze drie studies vergeleken25 en bleek op verschil-
lende dimensies te dalen bij patiënten met een diagnose mammacarcinoom, 
en juist significant te stijgen bij patiënten die een goedaardige aandoening 
bleken te hebben.
Samenvattend is er dus weinig bekend over distress en kwaliteit van leven bij 
een verdenking op longkanker, hetgeen opvalt vanwege het feit dat het gaat 
om een patiëntengroep die bekend staat om hoge angstscores gedurende het 
verdere verloop van de ziekte in vergelijking met andere maligniteiten.40,41 
Om meer te weten te komen over juist deze patiëntengroep is de PENELOPE-
studie ontworpen. PENELOPE is een acroniem voor Pulmonary Evaluation 
of NEoplastic Lesions in Outpatients and it’s Psychological Effects, en is uit-
gebreid beschreven in hoofdstuk 5. In het kort betrof de PENELOPE-studie 
een prospectief cohortonderzoek, met daarin een groot aantal patiënten die 
een diagnostisch traject doorliepen in verband met een verdenking op long-
kanker. Het doel was om angst, depressie en kwaliteit van leven te vergelijken 
tussen een groep patiënten die in een sneldiagnostiekprogramma werden 
geanalyseerd, en een groep die deze analyse via stapsgewijze diagnostiek 
onderging. De groepen waren verdeeld over vier ziekenhuizen, twee daarvan 
met een sneldiagnostiektraject, en twee die patiënten stapsgewijs analyseer-
den. Patiënten beantwoordden wekelijks diverse vragenlijsten met betrek-
king tot angst, depressie en kwaliteit van leven op vaste momenten vóór en 
tijdens het diagnostische traject gedurende zes weken, met een laatste vra-
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genlijst drie maanden daarna. De uiteindelijke analyse betrof de resultaten 
van de HADS waar het ging om angst en depressie,18 en op het gebied van 
kwaliteit van leven de resultaten van de 30-items tellende European Organi-
zation for Research and Treatment of Cancer 30-item Quality of Life Questi-
onnaire (QLQ-C30)42 en de bijbehorende longkankerspecifieke module met 
13 items (QLQ-LC13).43 In totaal beantwoordden 193 patiënten tenminste één 
vragenlijst. De pre-diagnostische scores voor distress bleken zeer hoog. De 
gemiddelde HADS-totaalscore bedroeg 13.5, of anders gezegd: 63.4% van 
alle patiënten hadden een HADS-totaalscore van 10 of hoger, indicatief voor 
significante distress. Deze pre-diagnostische waarden verschilden niet tus-
sen patiënten die sneldiagnostiek of stapsgewijze diagnostiek doorliepen. 
Opvallend was wel dat patiënten die uiteindelijk daadwerkelijk longkanker 
bleken te hebben, significant meer pre-diagnostische distress hadden in ver-
gelijking met patiënten die een benigne diagnose kregen (14.7 versus 11.8, p 
= 0.01). De pre-diagnostische kwaliteit van leven, weergegeven door de glo-
bale kwaliteit van leven-schaal van de QLQ-C30 bedroeg 61.6 en dit verschil-
de niet tussen beide diagnostische trajecten. Bij sneldiagnostiekpatiënten 
daalde de gemiddelde HADS-totaalscore gedurende de eerste zes weken van 
de studie van 13.8 naar 11.9, maar bij patiënten die stapsgewijze diagnostiek 
doorliepen bleef deze hoog (respectievelijk 13.1 en 13.6), waarbij een signifi-
cant (p = 0.03) interactie-effect zichtbaar werd tussen de soort diagnostiek (2) 
en tijd (7 meetmomenten). Een soortgelijke interactie werd gevonden voor de 
gemiddelde HADS-A subscore. Bij afzonderlijke analyse van bovenstaande 
gegevens bleek dit effect vooral voor mannen (p = 0.04) en patiënten met een 
maligne aandoening (p = 0.03) te gelden, maar niet voor vrouwen (p = 0.49) 
of patiënten met een benigne diagnose (p = 0.78). Op het laatste meetmo-
ment na drie maanden bleek geen verschil meer te bestaan tussen de snel-
diagnostiek en stapsgewijze diagnostiek waar het ging om de HADS-totaal-
score (respectievelijk 11.5 en 11.8, p = 0.91). Wel lagen de scores van patiënten 
met de diagnose longkanker duidelijk hoger dan die van patiënten met een 
benigne diagnose (respectievelijk 13.2 en 8.5, p = 0.01). De gemiddelde pre-
diagnostische globale QLQ-C30 kwaliteit van leven-score viel binnen de be-
kende referentiewaarden voor longkankerpatiënten44 en verschilde niet tus-
sen sneldiagnostiek en stapsgewijze diagnostiek. Evenmin viel er een 
relevante verandering waar te nemen tijdens de looptijd van de studie.
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AlgeMene discussie
In de zorg voor patiënten met longkanker is de laatste decennia veel veran-
derd. Zoals eerder al genoemd, lijken vooral in Nederland de aantallen pa-
tiën ten alleen maar te stijgen.3 Het vaststellen van het exacte tumortype en 
het correcte stadium zijn steeds belangrijker geworden, omdat de keuze voor 
de behandeling sterk afhankelijk is geworden van de combinatie van stadi-
um, tumortype en vaak ook mutatiestatus.45,46 Hier kan sneldiagnostiek een 
centrale rol spelen. Dit proefschrift toont aan dat sneldiagnostiek enerzijds 
de longarts in staat stelt om longkanker zo goed te diagnosticeren en stadi-
eren als binnen de reguliere diagnostiek mogelijk is, en wat de doorlooptij-
den betreft binnen de criteria van de richtlijnen te blijven. Het heeft ander-
zijds zeker ook voor de patiënt een meerwaarde vanwege een beter psychisch 
welbevinden in de periode rondom de diagnose.
het snelDiagnostiekProgramma voor longkanker
diagnostiek
Het sneldiagnostiekprogramma voor longkanker in het Radboudumc, dat in 
de hoofdstukken 2 en 3 uitgebreid beschreven is, bestaat uit twee unieke 
elementen. Het programma start bij iedere patiënt met een diagnostische 
FDG-PET/CT. Daarnaast werd als primaire diagnostische modaliteit voor 
weefseldiagnostiek gekozen voor bronchoscopie. Met name het laatste is 
wellicht niet altijd de meest optimale keuze; indien er sprake is van kleinere 
of perifeer gelegen afwijkingen kan transthoracale biopsie, echo- of CT-
geleid, of een bronchoscopie ondersteund met moderne navigatie technie-
ken, meer geschikt zijn. Verder beschikken de meeste klinieken tegenwoor-
dig over endobronchiale echografie (EBUS), waarmee diagnostiek en 
stadiëring van mediastinale lymfeklieren in één onderzoek zijn te combine-
ren. Desondanks werd bij 59.1% van alle longkankerpatiënten de diagnose 
bronchoscopisch gesteld. Daar komt bij dat, hoewel bij 60.9% van alle long-
kankerpatiënten geen endobronchiale afwijkingen werden aangetroffen, bij 
39.4% van hen toch maligne cellen werden aangetroffen. Dit wijst op een 
meerwaarde van de bronchoscopie in ervaren handen. De inspanning van de 
pathologische analyse voor een snelle diagnose is uiteraard ook van groot 
belang, maar bleek desondanks nog steeds kwalitatief hoogwaardig: in 
97.2% van de gevallen van longkanker bleek de voorlopige diagnose die bron-
choscopisch was geconstateerd en op dezelfde dag met de patiënt besproken 
werd, na volledige analyse van al het materiaal later in de week correct te zijn. 
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Hoewel de kleinere hoeveelheid materiaal voor diagnostiek bij cytologie (ver-
geleken met histologie) in een aanzienlijk deel van de gevallen correct kan 
zijn, houdt de beperkte hoeveelheid mogelijk wel een beperking in voor mu-
tatie-analyse op het genetisch materiaal. Dit is inmiddels van toepassing op 
een deel van de longkankerpatiënten,46 maar was nog niet gebruikelijk in de 
geanalyseerde jaren van het cohortonderzoek. 
Het belangrijkste onderzoek in het sneldiagnostiekprogramma (ook het eer-
ste dat de patiënt ondergaat) is de FDG-PET/CT, die door de radioloog en 
nucleair geneeskundige gezamenlijk terstond wordt verslagen. In hoofdstuk 
3 is aangetoond dat de sensitiviteit, zelfs voor de groep van patiënten die 
verwezen werd met een X-thorax, negatief en positief voorspellende waarde 
van de FGD-PET/CT binnen het sneldiagnostiekprogramma, gelijkwaardig 
zijn aan de diagnostische kwaliteiten zoals gedocumenteerd in de weten-
schappelijke literatuur.47 Weliswaar viel de specificiteit in deze vergelijking 
lager uit met 60.2% ten opzichte van gemiddeld 77.8%, maar dan moet wel 
benadrukt worden dat in andere studies over de diagnostische waarde van 
FDG-PET/CT het doorgaans solitaire noduli betrof op CT – en dat verhoogde 
uiteraard de voorafkans op maligniteit.
Een belangrijk nadeel van FDG-PET/CT als eerste onderzoek is overdiagnos-
tiek bij patiënten die uiteindelijk geen maligne aandoening blijken te heb-
ben. In het geanalyseerde cohort betrof dit 34.8% van alle patiënten met een 
eenduidige of waarschijnlijk (na poliklinisch vervolgen) goedaardige diag-
nose. Waarschijnlijk is het risico op overdiagnostiek groter bij patiënten die 
met een X-thorax verwezen worden in plaats van met een tussentijdse CT-
thorax, aangezien een CT een afwijking veel beter als verdacht kan karakte-
riseren dan een X-thorax. Wanneer afzonderlijk gekeken werd naar de met 
FDG-PET en CT verkregen diagnostische gegevens, had retrospectief bij 8.3% 
van alle patiënten die met X-thorax waren verwezen een CT-thorax alléén met 
voldoende zekerheid maligniteit uit kunnen sluiten. Het afzonderlijk ver-
richten van CT vóór de FDG-PET kost echter meer tijd en kan een programma 
voor sneldiagnostiek logistiek ingewikkelder maken.
tijdigheid
Wellicht het meest waardevolle aspect van sneldiagnostiek is de zeer korte 
doorlooptijd tot het verkrijgen van een diagnose: mediaan twee dagen, zelfs 
één dag voor de subgroep van patiënten die verwezen zijn met een X-thorax. 
Dit is aanzienlijk korter dan de criteria uit richtlijnen12-15 en de gerappor-
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teerde doorlooptijden uit studies, die 7 tot wel 37 dagen lang kunnen zijn.16 
Uit het perspectief van de patiënt en uit het oogpunt van kwaliteit van zorg 
zijn echter ook de doorlooptijden vóór en na de diagnose van groot belang. 
Nadere analyse van overige doorlooptijden leverde aanwijzingen voor aan-
vullend gunstige effecten van een programma sneldiagnostiek. De wachttijd 
van de diagnose tot de therapeutische behandeling voor longkanker bedroeg 
mediaan 18 dagen, hetgeen ruim binnen de norm valt van de richtlijnen12-15 
en in de lage regionen van andere studies.16 De mediane wachttijd van ver-
wijzing tot het eerste bezoek was 7 dagen, langer dus dan de maximaal ac-
ceptabele wachttijd van 5 dagen in de Nederlandse richtlijn,15 maar vallend 
binnen de internationale richtlijnen.12-14 Een schema op vaste dagen (in het 
geval van dit sneldiagnostiekprogramma woensdag en donderdag) zal onver-
mijdelijk leiden tot een vertraging van enkele dagen voor een deel van de 
verwezen patiënten. De verwijstijd is echter korter wanneer deze wordt ver-
geleken met de uitkomsten in de wetenschappelijke literatuur,16 met uitzon-
dering van één publicatie.48 Dit suggereert dat, hoewel het sneldiagnostiek-
programma niet specifiek ontworpen is om de verwijsduur en wachttijd tot 
behandeling te verkorten, deze aanpak de gunstige effecten op dit gebied zou 
kunnen verklaren.
Distress en kwaliteit van leven ronDom De Diagnose
lessen uit penelope
Er is veel discussie geweest over de mogelijke positieve dan wel nadelige ef-
fecten van sneldiagnostiek voor de patiënt met een verdenking op longkan-
ker. Enerzijds is er altijd belang gehecht aan de tijd die een patiënt nodig zou 
hebben om te kunnen ‘wennen’ aan de kwalijke diagnose, anderzijds is be-
argumenteerd dat het zoveel mogelijk bekorten van de periode van onzeker-
heid voor patiënten beter zou zijn.49-51 De argumenten over en weer waren 
echter meer gestoeld op persoonlijke voorkeur en gevoel dan op de resulta-
ten van wetenschappelijk onderzoek. Er waren immers weinig publicaties 
over psychisch welbevinden en kwaliteit van leven rondom het diagnostische 
traject, en zoals in hoofdstuk 4 beargumenteerd, al helemaal niet als het 
ging om de invloed van een sneldiagnostiekprogramma. De PENELOPE-stu-
die, zoals beschreven in hoofdstuk 5, is feitelijk de eerste grote prospectieve 
studie geweest onder longkankerpatiënten naar de effecten van sneldiagnos-
tiek. Bij patiënten die op deze wijze waren geanalyseerd bleek distress sneller 
te verminderen dan bij analyse door stapsgewijze diagnostiek. De mogelijke 
verklaring is het kortere tijdsinterval en daardoor een kortere periode van 
onzekerheid, of het positieve effect van een geprogrammeerde aanpak die de 
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patiënt gedurende het traject steun biedt. Uiteraard moet niet vergeten wor-
den dat PENELOPE geen gerandomiseerde maar een beschrijvende studie 
was, en dat er verschillen waren in de kenmerken en aantallen van geïnclu-
deerde patiënten tussen verschillende centra. Anderzijds vormt de totale pa-
tiëntenpopulatie (evenals die beschreven in de analyses van het sneldiagnos-
tiekprogramma van het Radboudumc) een afspiegeling van de gemiddelde 
Nederlandse longkankerpatiënt. 
Naast het positieve effect op het psychisch welbevinden van de sneldiagnos-
tiekpatiënt, kwamen in de PENELOPE-studie twee andere bevindingen aan 
het licht. In de eerste plaats dat het niveau van distress bij patiënten bij wie 
longkanker wordt vermoed en die in afwachting zijn van het diagnostische 
traject zeer hoog is: bij bijna tweederde van de patiënten was dit dermate 
hoog (te weten een HADS-totaalscore van 10 of hoger)19 dat feitelijk sprake 
zou kunnen zijn van een psychische stoornis. Dit is weliswaar enigszins ver-
gelijkbaar met bevindingen uit de beperkte beschikbare literatuur,22-24-27 
maar in zekere zin toch een bijzondere uitkomst, omdat altijd rekening ge-
houden moet worden met het feit dat bij het vrouwelijk geslacht en bij een 
lagere leeftijd vaker sprake is van distress. Daarnaast is ook de soort kanker 
van invloed.40,54-57 Gezien het feit dat de meeste gegevens over distress bij een 
mogelijke diagnose van een maligniteit afkomstig zijn uit studies die in gro-
te meerderheid patiënten met een mammacarcinoom betreffen (die in stu-
dies alle van het vrouwelijk geslacht zijn en vaak jonger), lenen deze zich niet 
automatisch voor extrapolatie naar andere maligniteiten. Desondanks lijkt 
distress bij de in de PENELOPE-studie onderzochte longkankerpatiënten zo 
ernstig, dat geconcludeerd mag worden dat deze patiënten een risicogroep 
vormen. Daarnaast is dit een belangrijke bevinding, omdat de enige studie 
die eerder bij longkankerpatiënten is verricht, opvallend veel minder distress 
liet zien.26 Daarbij moeten we opmerken dat in deze studie waarschijnlijk een 
deel van de patiënten al op de hoogte was van de diagnose. Verder bleek dat 
de HADS-totaalscore drie maanden na diagnose bij patiënten in beide diag-
nostische benaderingen nog steeds ruim boven de 10-puntengrens lag. Deze 
uitkomst bevestigt dat de longkankerpatiënt beslist een categorie vertegen-
woordigt die een verhoogd risico loopt op psychische klachten. Dit besef is 
des te belangrijker omdat psychische klachten bij patiënten met kanker vaak 
niet aan het licht komen doordat ze niet gemeld worden, of doordat artsen 
ze onderschatten.52,53 Dit geldt niet alleen na de diagnose en behandeling, 
maar ook ervóór.
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het effect van sneldiagnostiek
Naast de bovengenoemde factoren die van invloed zijn op het psychisch wel-
bevinden, bracht hoofdstuk 4 aan het licht dat bij de diverse publicaties die 
verschenen zijn over distress bij de diagnose van kanker verschillende vra-
genlijsten werden gebruikt, die onderling moeilijk vergelijkbaar zijn. Een 
andere potentieel verwarrende factor is dat bepaalde studies niet het gehele 
diagnostische traject in ogenschouw nemen, maar bijvoorbeeld slechts een 
enkele ingreep. Dit alles maakt het lastig om de effecten van de snelheid van 
een diagnose van kanker op het psychisch welbevinden te generaliseren. 
Desondanks is de conclusie gerechtvaardigd dat er een gunstig effect op psy-
chisch welbevinden uitgaat van een snelle diagnose van een benigne afwij-
king, en dat bij bevestiging van het vermoeden van een maligniteit het psy-
chisch welbevinden zeker niet nadelig beïnvloed wordt door een snellere 
diagnose. Omgekeerd is een gunstige invloed van een snelle maligne diag-
nose aangetroffen in twee studies; deze uitzonderingen zijn mogelijk te ver-
klaren uit het feit dat één van beide studies patiënten met een melanoom 
betrof (waarbij de diagnostische excisie tevens vaak al de behandeling zelf 
betreft).39 In het andere geval betrof het een studie waarbij patiënten bij wie 
een ovariumcarcinoom werd vermoed een diagnostische buikoperatie on-
dergingen en de auteurs het vermoeden van additionele preoperatieve dis-
tress als factor benoemen (en er dus sprake van verstoring zou kunnen zijn).38 
Eigenlijk lenen slechts drie publicaties zich voor vergelijking met de PENE-
LOPE-studie. Het gaat om relatief kleine studies over patiënten met een ver-
denking van een mammacarcinoom, waarbij sneldiagnostiek vergeleken is 
met stapsgewijze diagnostiek.22,24,25 In deze studies daalden de angstscores 
duidelijk eerder bij een snellere benigne diagnose in een traject van sneldiag-
nostiek. In tegenstelling tot de PENELOPE-studie, waarin distress niet signi-
ficant verergerde na diagnose, was dit in deze studies wel het geval, waarbij 
overigens geen verschil viel aan te tonen tussen sneldiagnostiek en reguliere 
diagnostiek. Ter nuancering valt op te merken dat de studies slechts twee of 
drie meetmomenten hadden, mogelijk te kort om een daling van scores over 
de tijd waar te nemen. Bovendien waren er relatief weinig patiënten met een 
maligne diagnose (9-16%) en werd in de enige studie die de HADS als vragen-
lijst gebruikte, niet specifiek naar totaalscores gekeken.25 
Het verloop van kwaliteit van leven in de PENELOPE-studie (de QLQ-C30 glo-
bale kwaliteit van leven schaal) was anders dan die van de HADS-totaalscore: 
de pre-diagnostische kwaliteit van leven bleek vergelijkbaar met de referen-
tiewaarden voor longkankerpatiënten na diagnose58 en liet daarna geen rele-
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vante veranderingen zien. Noch over de tijd, noch tussen sneldiagnostiek en 
stapsgewijze diagnostiek. Opvallend is dat dit gegeven dan weer contrasteert 
met de dalende kwaliteit van leven-scores na sneldiagnostiek in de enige 
twee andere uit de literatuur bekende studies die kwaliteit van leven in dit 
kader bekeken.25,59 
De toekomst
Sneldiagnostiek heeft wezenlijke voordelen ten opzichte van stapsgewijze 
diagnostiek, maar verbetering lijkt mogelijk. Om de stralenbelasting voor 
een deel van de patiënten te verminderen en wellicht de kosteneffectiviteit te 
verbeteren, valt bijvoorbeeld te kiezen voor het scheiden en separaat beoor-
delen van de CT-thorax en de FDG-PET. Hierdoor blijft een klein deel van de 
patiënten die radiologisch benigne afwijkingen hebben de FDG-PET be-
spaard, zij het dat de complexiteit van het programma hierdoor wel toe-
neemt. Bovendien zal een tweedaags programma hierdoor vrijwel onmoge-
lijk worden. Een tweede mogelijkheid tot verbetering kan zijn om het pri-
maire onderzoek met als doel een weefseldiagnose te verkrijgen niet te 
beperken tot bronchoscopie, maar uit te breiden met bijvoorbeeld transtho-
racale puncties en endo-echografie. Dit zal met name de tijdigheid van de 
diagnostiek verbeteren voor patiënten met perifeer gelegen afwijkingen of 
mediastinale metastasen. Tenslotte is, zeker uit het perspectief van patiën-
ten, de wachttijd van verwijzing en die tot het starten van de behandeling 
tenminste zo belangrijk als de doorlooptijd van diagnostiek. Indien de aan-
dacht hiervoor afneemt, heeft het minimaliseren van de diagnostische door-
looptijd weinig meerwaarde.
Dit proefschrift heeft laten zien dat sneldiagnostiek bij een verdenking op 
longkanker niet alleen evidente voordelen heeft voor een tijdige en correcte 
diagnose, maar bovendien vergeleken met stapsgewijze diagnostiek een 
gunstig effect heeft op het psychisch welbevinden van patiënten die de diag-
nostiek moeten ondergaan. Tot het moment dat er genezing wordt gevonden 
voor longkanker zullen deze patiënten een risicogroep blijven voor distress. 
Niet alleen in de periode van de diagnose, maar ook gedurende de behande-
ling, zowel curatief als palliatief, en daarna. Genezing is bij lange na niet in 
zicht, hetgeen de beroepsgroep zou moeten dwingen om alert te zijn op de 
mogelijke ernstige psychische klachten die kunnen ontstaan vanaf het mo-
ment dat een vermoeden van longkanker wordt uitgesproken. 
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dAnkwoord
Een proefschrift zou gezien kunnen worden als het product van inspiratie en inspan-
ning. De inspiratie ontstond door mijn omgang met patiënten, verdacht van een 
vorm van longkanker, die ik zag in het sneldiagnostiek-programma in het Rad-
boudumc, en verdiepte zich na augustus 2005 met de publicatie van het artikel ‘De 
Snelheidsduivel’ in Medisch Contact. Een kritisch artikel, waarbij mij opviel dat de 
wetenschappelijke argumenten ontbraken die vóór sneldiagnostiek pleiten. Ook de 
stelling dat het bundelen van onderzoek en het gesprek over de uitslag emotionele 
consequenties kan hebben voor de patiënt, is mij bijgebleven. De verbazing over het 
ontbreken van bewijs in de conclusies bij een patiëntencategorie die me zo na aan 
het hart ligt, heeft het toen gewonnen van de argwaan over de omvang en de haal-
baarheid van een promotieonderzoek. De inspanningen volgden niet geheel automa-
tisch, maar wel gestaag. Door het combineren van mijn werk als longarts in het Rad-
boudumc, later in het HAGA ziekenhuis, en het onderzoek kan ik bevestigen dat het 
stevig, maar haalbaar is. Het vereist coöperatie, keuzes en efficiëntie, maar boven-
dien het accepteren van teleurstellingen en tot slot flexibiliteit. Zoals met zoveel in 
het leven kan je dat natuurlijk niet alleen, en daarom wil ik een aantal personen 
graag bedanken.
In de allereerste plaats ben ik dank verschuldigd aan alle patiënten die belangeloos 
hebben meegewerkt aan de PENELOPE-studie, en aan de verpleegkundigen, nurse-
practitioners en longartsen die zich voor hun deelname hebben ingezet.
Promotor Richard Dekhuijzen gaf mij het gevoel van onvoorwaardelijk vertrouwen 
en bleef mij motiveren door de jaren heen, niet alleen tijdens mijn opleiding tot 
longarts, maar ook in de periode daarna. Hij is een continue steun geweest voor het 
onderzoek en voor mijn carrière.
Judith Prins begon als copromotor, maar na haar eigen promotie tot hoogleraar be-
schikte ik over twee promotoren. Ik ben haar dankbaar voor alle inspanningen en 
steun, voor de flexibiliteit bij het vrijmaken van tijd voor overleg ondanks haar druk-
ke werkzaamheden, maar bovenal voor haar positieve instelling en humor, die me 
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op een aantal momenten de juiste zet voorwaarts hebben gegeven. Tijdens de een-
zame uren achter mijn computerscherm was zij als het nodig was op afstand toch 
steeds in de buurt.
Copromotor Erik van der Heijden wil ik graag bedanken vanwege zijn niet-aflatende 
enthousiasme voor het hele project, zijn sterke motivatie om sneldiagnostiek breed 
te analyseren en de tijd en steun die hij me daarvoor heeft gegeven. Mijn overgang 
naar Den Haag heeft niet verhinderd dat ik toch nog veel van hem heb kunnen leren, 
onder andere op endo-echoscopisch gebied. Ik heb de onderlinge samenwerking van 
Judith, Erik en mij als uniek ervaren, en zal deze missen.
Lioe-Fee de Geus-Oei werd copromotor vanaf het moment dat Judith plaats maakte, 
maar had hieraan voorafgaand al vele malen intensief meegekeken en meegedacht 
tijdens het schrijven van de artikelen over het sneldiagnostiek-programma in het 
Radboudumc en de rol van de PET/CT. Ik mocht profiteren van haar enthousias me 
voor het hele project en haar ongeëvenaarde doorzettingsvermogen.
Ook had ik graag Ria te Winkel willen bedanken. Zij heeft een prominente plaats 
ingenomen en mij veel werk uit handen genomen door de antwoorden van alle vra-
genlijsten te digitaliseren. Het is heel triest dat zij ziek werd en overleed. Ik weet ze-
ker dat ze de uitkomsten van het onderzoek boeiend had gevonden.
Door Hanneke van Helvoort werd de moeizame omgang met het niet altijd even ge-
bruiksvriendelijke statistiekprogramma SPSS enigszins draaglijk. Ik heb bij herha-
ling mogen profiteren van haar toegankelijke, heldere inzicht en kwam zo weer op 
het goede spoor terecht.
Mijn collega’s in het HAGA ziekenhuis, in alfabetische volgorde Harry Heijerman, 
Hassan El Bouazzaoui, Henk Schreur, Joey Brahim, Johnny Daflaar, Klara Rijnten, 
Renske van der Meer, Saar van Nederveen, Tessa Nizet, maar vooral mijn oncologi-
sche ‘buddy’ Henk Codrington, wil ik eveneens graag bedanken voor hun flexibiliteit 
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en steun tijdens de reguliere werkzaamheden en opleiding, waardoor ik in staat bleef 
tijd te besteden aan het onderzoek. 
Coauteur Rogier Donders wil ik graag bedanken voor zijn inzet bij de analyses van 
de PENELOPE-studie en het bijbehorende artikel. Het is een ware kunst om statisti-
sche kennis over te brengen op een simpele longarts.
Ik mocht steunen op twee bijzondere paranimfen. Ik ben erg dankbaar dat ze op 
deze bijzondere dag aan mijn zijde willen staan. In Joris van Gulick heb ik al vele 
jaren een echte en unieke vriend, in goede en minder goede tijden. We mogen wat 
persoonlijkheid betreft verschillen, onze vriendschap bewijst dat je desondanks 
zoveel kan delen. De vriendschap met Annemarie Cottaar is op een andere manier 
uniek. Niet alleen doordat deze is ontstaan uit een arts-patiëntrelatie, maar vooral 
door de manier waarop we vervolgens een onvoorwaardelijke en diepe band hebben 
kunnen ontwikkelen die ik, ondanks de onzekere toekomst, nooit had willen mis-
sen. Zij heeft haar rol als paranimf beslist waargemaakt door, samen met haar man 
Wim Willems, een belangrijke motivator te zijn tijdens het schrijven van het manus-
cript. Haar contacten met vormgeefster Suzan Beijer en ervaringen met illustratoren 
en drukkers hebben mij veel zorgen uit handen genomen.
Ze zullen het vast heel vanzelfsprekend vinden, maar ik ben mijn ouders Ria en Jos 
erg dankbaar; niet alleen voor hun onvoorwaardelijke steun en interesse in de vele 
ontwikkelingen die ik van kinds af doormaakte, maar ook voor alle levenslessen die 
ik van hen heb gekregen. Evenals op mijn broer Reinout, weet ik dat ik altijd op hen 
kan rekenen. 
En moet je je eigen partner bedanken? Jeroen had geen andere keuze dan deel genoot 
te zijn van alle mooie en minder mooie kanten van het schrijven aan dit proefschrift. 
Hij zal het waarschijnlijk maar raar vinden dat ik hem bedank voor zijn geduld, zijn 
humor, zijn eerlijkheid en zijn vermogen om te delen in grote maar ook heel kleine 
dingen. Hij mag ervan denken wat hij wil, met niemand anders zou ik dit dankwoord 
willen besluiten.
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curriculuM vitAe
pepIjn BroCken is geboren op 13 maart 1975 in Boxtel. Na het gymnasium Beek-
vliet in St. Michielsgestel doorlopen te hebben, begon hij in 1993 aan de studie  
Geneeskunde in Nijmegen. Hij werkte tijdens zijn studie als huisarts-achterwacht, 
maar musiceerde ook als violist en altviolist in het Meijerijs Kamerorkest,  
Nijmeegs Studentenorkest en het Nederlands Studentenorkest. Na afronding van 
het artsexamen in 1999 werkte hij als Assistent Geneeskunde Niet In Opleiding 
(AGNIO) in het Canisius Wilhelmina Ziekenhuis te Nijmegen, waar hij vervolgens  
de opleiding startte tot internist. In 2003 besloot hij zich verder te specialiseren  
tot longarts in het Radboudumc, onder de hoede van opleider prof. dr. P.N.R. 
Dekhuijzen. In die tijd was hij als arts-assistent actief in het assistenten-bestuur  
en concilium van de Nederlandse Vereniging van Artsen voor Longziekten en  
Tuberculose (NVALT). In de latere fase van deze opleiding ontstond een steeds 
grotere interesse voor de pulmonale oncologie, en begon hij aan het onderzoek  
dat de basis vormde voor dit proefschrift. Na anderhalf jaar als chef de clinique 
gewerkt te hebben in het Radboudumc is hij sinds 2009 als longarts verbonden  
aan het HAGA ziekenhuis in Den Haag, met aandachtsgebied pulmonale  
oncologie en endobronchiale echoscopie. 
P.Brocken_170x240mm_bw_v13.indd   119 05-01-15   14:32
Deze publicatie is mede mogelijk gemaakt door:
roChe nederland B.v.
alMIrall B.v.
© Januari 2015 Pepijn Brocken
Illustratie omslag Roland Blokhuizen
Vormgeving Suzan Beijer
isBn 978 90 823137 0 3






impacT of pracTice organizaTion 




























P.Brocken_170x240mm_rug7.8mm_v01.indd   1 05-01-15   14:36
